**Table 4. Outcomes reported for Key Question 2, 3, and 4**

| **Author, Year** | **Outcome** | **Followup Time** | **Assay** | **Cutpoint** | **Incidence of Outcome** | **Measures of Association** | **AUC** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Abaci, 20041 | All-cause mortality | Years: 2 | NR | NR | Pts with event: 25 / 25 persons  Results: unadjusted | NR | NR |
| Abaci, 20041 | All-cause mortality | Years: 2 | Assay: cTnI  Mfg: other  Mfg: Abbott; other; Axsym | > 0.5 mcg/L | Pts with event: 10 / 25 persons  Results: unadjusted | N: 31  log rank: 5.15  p value: 0.0232;  ref group: other;  ref group: All TnI | NR |
| Abaci, 20041 | All-cause mortality | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.03 mcg/L | Pts with event: 6 / 25 persons  Results: unadjusted | N: 75 | NR |
| Abaci, 20041 | All-cause mortality | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | Pts with event: 13 / 25 persons  Results: unadjusted | N: 27  log rank: 23.85  p value: <0.0001;  ref group: Other;  ref group: All TnT | NR |
| Abaci, 20041 | All-cause mortality | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | 0.03-0.1 mcg/mL | Pts with event: 6 / 25 persons  Results: unadjusted | NR | NR |
| Abaci, 20041 | Cardio mortality | Years: 2 | NR | NR | Pts with event: 12 / 12 persons  Results: unadjusted | NR | NR |
| Abaci, 20041 | Cardio mortality | Years: 2 | Assay: cTnI  Mfg: other  Mfg: Abbott; other; Axsym | > 0.5 mcg/L | Pts with event: 7 / 12 persons  Results: unadjusted | NR | NR |
| Abaci, 20041 | Cardio mortality | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.03 mcg/L | Pts with event: 3 / 12 persons  Results: unadjusted | NR | NR |
| Abaci, 20041 | Cardio mortality | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | Pts with event: 5 / 12 persons  Results: unadjusted | NR | NR |
| Abaci, 20041 | Cardio mortality | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | 0.03-0.1 ug/mL | Pts with event: 4 / 12 persons  Results: unadjusted | NR | NR |
| Abbas, 20052 | All-cause mortality | NR | Assay: cTnI  Mfg: Bayer; other; ADVIA Centaur | < 0.07 mcg/L | Pts with event: 1 / 177 persons  Results: adjusted | N: 177  OR: 1 | NR |
| Abbas, 20052 | All-cause mortality | NR | Assay: cTnI  Mfg: Bayer; other; ADVIA Centaur | > 0.07 mcg/L | Pts with event: 7 / 38 persons  Results: adjusted | N: 38  OR: 2.439  95% CI: 0.771 to 6.977  p value: 0.0786;  ref group: Grp3 | NR |
| Abbas, 20052 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | < 0.01 mcg/L | Pts with event: 0 / 127 persons  Results: adjusted | N: 127  OR: 1 | NR |
| Abbas, 20052 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.01 mcg/L | Pts with event: 16 / 95 persons  Results: adjusted | N: 95  OR: 3.471  95% CI: 1.274 to 10.394  p value: 0.0075;  ref group: Grp1 | NR |
| Acharji, 20123 | All-cause mortality | Days: 30 | NR | Greater than upper limit of lab normal | % Pts with event: 11.9% / 1291 persons | N: 1291  RH: 2.05  95% CI: 1.48 to 2.83  p value: <0.0001;  ref group: Grp2 | NR |
| Acharji, 20123 | All-cause mortality | Days: 30 | NR | Lower than upper limit of lab normal | % Pts with event: 5.6% / 888 persons | N: 888 | NR |
| Acharji, 20123 | All-cause mortality | Years: 1 | NR | Greater than upper limit of lab normal | % Pts with event: 20.9% / 1291 persons | N: 1291  RH: 1.72  95% CI: 1.36 to 2.17  p value: <0.0001;  ref group: Grp2 | NR |
| Acharji, 20123 | All-cause mortality | Years: 1 | NR | Lower than upper limit of lab normal | % Pts with event: 13.1% / 888 persons | N: 888  RH: 1 | NR |
| Apple, 19975 | Cardio mortality | Years: 1 | Assay: cTnI  Mfg: NR; NR | < 0.8 mcg/L | Pts with event: 1 / 13 persons  Results: unadjusted | NR | NR |
| Apple, 19975 | Cardio mortality | Years: 1 | Assay: cTnI  Mfg: NR; NR | > 0.8 mcg/L | Pts with event: 3 / 3 persons  Results: unadjusted | NR | NR |
| Apple, 19975 | Cardio mortality | Years: 1 | Assay: cTnT  Mfg: other  Mfg: Boehringer; other; ELISA | < 0.2 mcg/L | Pts with event: 0 / 4 persons  Results: unadjusted | NR | NR |
| Apple, 19975 | Cardio mortality | Years: 1 | Assay: cTnT  Mfg: other  Mfg: Boehringer; other; ELISA | > 0.2 mcg/L | Pts with event: 4 / 12 persons  Results: unadjusted | NR | NR |
| Apple, 19975 | Other composite (unstable angina) | Years: 1 | Assay: cTnI  Mfg: NR | < 0.8 mcg/L | Pts with event: 2 / 13 persons  Results: unadjusted | NR | NR |
| Apple, 19975 | Other composite (unstable angina) | Years: 1 | Assay: cTnI  Mfg: NR | > 0.8 mcg/L | Pts with event: 0 / 3 persons  Results: unadjusted | NR | NR |
| Apple, 19975 | Other composite (unstable angina) | Years: 1 | Assay: cTnT  Mfg: other  Mfg: Boehringer; other; ELISA | < 0.2 mcg/L | Pts with event: 1 / 4 persons  Results: unadjusted | NR | NR |
| Apple, 19975 | Other composite (unstable angina) | Years: 1 | Assay: cTnT  Mfg: other  Mfg: Boehringer; other; ELISA | > 0.2 mcg/L | Pts with event: 1 / 12 persons  Results: unadjusted | NR | NR |
| Apple, 20027 | All-cause mortality | Years: 3 | Assay: cTnI  Mfg: Dade Behring; dimension | < 0.1 mcg/L | % Pts with event: 44% / 688 persons  Results: adjusted | N: 688  RR: 1 | NR |
| Apple, 20027 | All-cause mortality | Years: 3 | Assay: cTnI  Mfg: Dade Behring; dimension | > 0.1 mcg/L | % Pts with event: 60% / 45 persons  Results: adjusted | N: 45  RR: 2.1  95% CI: 1.3 to 3.3  p value: 0.005;  ref group: Grp1 | NR |
| Apple, 20027 | All-cause mortality | Years: 3 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.01 mcg/L | % Pts with event: 8.4% / 132 persons  Results: adjusted | N: 132  RR: 1 | NR |
| Apple, 20027 | All-cause mortality | Years: 3 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.04 mcg/L | % Pts with event: 28% / 346 persons  Results: adjusted | N: 346  RR: 1 | NR |
| Apple, 20027 | All-cause mortality | Years: 3 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.1 mcg/L | % Pts with event: 42% / 585 persons  Results: adjusted | N: 585  RR: 1 | NR |
| Apple, 20027 | All-cause mortality | Years: 3 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.01 mcg/L | % Pts with event: 51% / 601 persons  Results: adjusted | N: 601  RR: 4.3  95% CI: 2.1 to 8.7  p value: <0.001;  ref group: Grp1 | NR |
| Apple, 20027 | All-cause mortality | Years: 3 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.04 mcg/L | % Pts with event: 57% / 387 persons  Results: adjusted | N: 387  RR: 2.1  95% CI: 1.6 to 3  p value: <0.001;  ref group: Grp1 | NR |
| Apple, 20027 | All-cause mortality | Years: 3 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | % Pts with event: 56% / 148 persons  Results: adjusted | N: 148  RR: 2.2  95% CI: 1.6 to 3  p value: <0.001;  ref group: Grp1 | NR |
| Apple, 20048 | All-cause mortality | Years: 2 | Assay: cTnI  Mfg: Beckman; other; AccuTnI | < 0.04 mcg/L | % Pts with event: 26% / 323 persons  Results: adjusted | N: 323  RR: 1 | NR |
| Apple, 20048 | All-cause mortality | Years: 2 | Assay: cTnI  Mfg: Beckman; other; AccuTnI | > 0.04 mcg/L | % Pts with event: 47% / 76 persons  Results: adjusted | N: 76  RR: 1.8  95% CI: 1.1 to 2.7  p value: 0.01;  ref group: Grp1 | NR |
| Apple, 20048 | All-cause mortality | Years: 2 | Assay: cTnI  Mfg: Dade Behring; dimension | < 0.1 mcg/L | % Pts with event: 28% / 379 persons  Results: adjusted | N: 379  RR: 1 | NR |
| Apple, 20048 | All-cause mortality | Years: 2 | Assay: cTnI  Mfg: Dade Behring; dimension | > 0.1 mcg/L | % Pts with event: 61% / 20 persons  Results: adjusted | N: 20  RR: 2.7  95% CI: 1.5 to 5  p value: 0.004;  ref group: Grp1 | NR |
| Apple, 20048 | All-cause mortality | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.01 mcg/L | % Pts with event: 11% / 60 persons  Results: adjusted | N: 60  RR: 1 | NR |
| Apple, 20048 | All-cause mortality | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.03 mcg/L | % Pts with event: 14% / 139 persons | N: 139  RR: 1 | NR |
| Apple, 20048 | All-cause mortality | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.01 mcg/L | % Pts with event: 33% / 339 persons  Results: adjusted | N: 339  RR: 2.8  95% CI: 1.5 to 5  p value: 0.01; ref group: Grp1 | NR |
| Apple, 20048 | All-cause mortality | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.03 mcg/L< 0.074 mcg/L | % Pts with event: 36% / 129 persons | N: 129  RR: 2.4  95% CI: 1.4 to 4.3  p value: <0.0001;  ref group: Grp1 | NR |
| Apple, 20048 | All-cause mortality | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.074 mcg/L | % Pts with event: 41% / 131 persons | N: 131  RR: 3.2  95% CI: 1.9 to 5.6  p value: <0.0001;  ref group: Grp1 | NR |
| Apple, 20079 | MACE < 1 year | NR | Assay: cTnI  Mfg: Beckman | < 0.1 males/0.04 females mcg/L | No. of events: 9 / 46 persons  Results: unadjusted | NR | NR |
| Apple, 20079 | MACE < 1 year | NR | Assay: cTnI  Mfg: Beckman | > 0.1males/0.04females mcg/L | No. of events: 8 / 18 persons  Results: unadjusted | NR | NR |
| Apple, 20079 | MACE < 1 year | NR | Assay: cTnI  Mfg: Dade Behring; dimension | < 0.06 mcg/L | No. of events: 8 / 46 persons  Results: unadjusted | NR | NR |
| Apple, 20079 | MACE < 1 year | NR | Assay: cTnI  Mfg: Dade Behring; dimension | > 0.06 mcg/L | No. of events: 10 / 25 persons  Results: unadjusted | NR | NR |
| Apple, 20079 | MACE < 1 year | NR | Assay: cTnI  Mfg: other  Mfg: Tosoh; other; AIA | < .07 males/0.06 females mcg/L | No. of events: 3 / 22 persons  Results: unadjusted | NR | NR |
| Apple, 20079 | MACE < 1 year | NR | Assay: cTnI  Mfg: other  Mfg: Tosoh; other; AIA | >.07males/0.06 females mcg/L | No. of events: 5 / 19 persons  Results: unadjusted | NR | NR |
| Apple, 20079 | MACE < 1 year | NR | Assay: cTnT  Mfg: Roche; Elecsys | < 0.01 mcg/L | No. of events: 2 / 17 persons  Results: unadjusted | NR | NR |
| Apple, 20079 | MACE < 1 year | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.01 mcg/L | No. of events: 14 / 45 persons  Results: unadjusted | NR | NR |
| Apple, 20079 | MACE < 1 year | NR | Assay: cTnI  Mfg: Beckman; access | <0.1males/0.04females mcg/L | No. of events: 5 / 61 persons  Results: unadjusted | NR | NR |
| Apple, 20079 | MACE < 1 year | NR | Assay: cTnI  Mfg: Beckman; access | >0.1males/0.04females mcg/L | No. of events: 4 / 13 persons  Results: unadjusted | NR | NR |
| Apple, 20079 | MACE < 1 year | NR | Assay: cTnI  Mfg: Dade Behring; dimension | < 0.06 mcg/L | No. of events: 5 / 67 persons  Results: unadjusted | NR | NR |
| Apple, 20079 | MACE < 1 year | NR | Assay: cTnI  Mfg: Dade Behring; dimension | > 0.06 mcg/L | No. of events: 4 / 16 persons  Results: unadjusted | NR | NR |
| Apple, 20079 | MACE < 1 year | NR | Assay: cTnI  Mfg: other  Mfg: Tosoh; other; AIA | <.07males/0.06 females mcg/L | No. of events: 2 / 41 persons  Results: unadjusted | NR | NR |
| Apple, 20079 | MACE < 1 year | NR | Assay: cTnI  Mfg: other  Mfg: Tosoh; other; AIA | >.07males/0.06 females mcg/L | No. of events: 5 / 16 persons  Results: unadjusted | NR | NR |
| Apple, 20079 | MACE < 1 year | NR | Assay: cTnT  Mfg: Roche; access | < 0.1 mcg/L | No. of events: 5 / 49 persons  Results: unadjusted | NR | NR |
| Apple, 20079 | MACE < 1 year | NR | Assay: cTnT  Mfg: Roche; access | > 0.1 mcg/L | No. of events: 4 / 24 persons  Results: unadjusted | NR | NR |
| Apple, 20079 | MACE < 1 year | NR | Assay: cTnI  Mfg: Beckman; access | < 0.1males/0.04females mcg/L | Pts with event: 11 / 252 persons  Results: unadjusted | NR | NR |
| Apple, 20079 | MACE < 1 year | NR | Assay: cTnI  Mfg: Beckman; access | > 0.1males/0.04females mcg/L | Pts with event: 0 / 26 persons  Results: unadjusted | NR | NR |
| Apple, 20079 | MACE < 1 year | NR | Assay: cTnI  Mfg: Dade Behring; dimension | < 0.06 mcg/L | Pts with event: 11 / 299 persons  Results: unadjusted | NR | NR |
| Apple, 20079 | MACE < 1 year | NR | Assay: cTnI  Mfg: Dade Behring; dimension | > 0.06 mcg/L | Pts with event: 0 / 31 persons  Results: unadjusted | NR | NR |
| Apple, 20079 | MACE < 1 year | NR | Assay: cTnI  Mfg: other  Mfg: Tosoh; other; AIA200 | < .07males/0.06females mcg/L | Pts with event: 9 / 181 persons  Results: unadjusted | NR | NR |
| Apple, 20079 | MACE < 1 year | NR | Assay: cTnI  Mfg: other  Mfg: Tosoh; other; AIA200 | > 0.07males/0.06females mcg/L | Pts with event: 1 / 22 persons  Results: unadjusted | NR | NR |
| Apple, 20079 | MACE < 1 year | NR | Assay: cTnT  Mfg: Roche; Elecsys | < 0.1 mcg/L | Pts with event: 9 / 243 persons  Results: unadjusted | NR | NR |
| Apple, 20079 | MACE < 1 year | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | Pts with event: 2 / 37 persons  Results: unadjusted | NR | NR |
| Artunc, 201210 | All-cause mortality | Days: 710  Followup NR | NR | NR | Results: unadjusted | NR | AUC: 0.665  Sens: 0.61  Spec: 0.7 |
| Artunc, 201210 | All-cause mortality | Days: 710  Followup NR | NR | NR | Results: unadjusted | NR | AUC: 0.684  Sens: 0.91  Spec: 0.41 |
| Artunc, 201210 | All-cause mortality | Days: 710  Followup NR | Assay: hs cTnI  Mfg: other  Mfg: Siemens; other; ADIVA Centaur | <10 pg/mL | % Pts with event: 14.8%  Results: unadjusted | RH: 1 | AUC: 0.665  Sens: 0.61  Spec: 0.7 |
| Artunc, 201210 | All-cause mortality | Days: 710  Followup NR | Assay: hs cTnI  Mfg: other  Mfg: Siemens; other; ADIVA Centaur | >22 pg/mL | % Pts with event: 29.9%  Results: unadjusted | RH: 2.87  to 6.51 | AUC: 0.665  Sens: 0.61  Spec: 0.7 |
| Artunc, 201210 | All-cause mortality | Days: 710  Followup NR | Assay: hs cTnI  Mfg: other  Mfg: Siemens; other; ADIVA Centaur | 10-22 pg/mL | % Pts with event: 15.5%  Results: unadjusted | RH: 1.23  95% CI: 0.472 to 3 | AUC: 0.665  Sens: 0.61  Spec: 0.7 |
| Artunc, 201210 | All-cause mortality | Days: 710  Followup NR | Assay: hs cTnT  Mfg: Roche; Elecsys | <37 pg/mL | % Pts with event: 7%  Results: unadjusted | RH: 1 | AUC: 0.684  Sens: 0.91  Spec: 0.41 |
| Artunc, 201210 | All-cause mortality | Days: 710  Followup NR | Assay: hs cTnT  Mfg: Roche; Elecsys | >68 pg/mL | % Pts with event: 29.1%  Results: unadjusted | RH: 6.01 to 20.6  p value: <.001;  ref group: Grp1 | AUC: 0.684  Sens: 0.91  Spec: 0.41 |
| Artunc, 201210 | All-cause mortality | Days: 710  Followup NR | Assay: hs cTnT  Mfg: Roche; Elecsys | 38-67 pg/mL | % Pts with event: 23%  Results: unadjusted | RH: 5.14  95% CI: 1.91 to 17.6  p value: <.01;  ref group: Grp1 | AUC: 0.684  Sens: 0.91  Spec: 0.41 |
| Assa, 201311 | All cause mortality  subgroup data : intra-HD change in cTnI levels |  | Assay: hs cTnI  Mfg: ARCHITECT STAT; NR | per 10 ng/L | Results: adjusted | N: 90 RH: 0.9  95% CI: 0.75 to 1.08  p value: 0.25;  ref group: cont. variable | NR |
| Assa, 201311 | All cause mortality  subgroup data:  postdialysis cTnI |  | Assay: hs cTnI  Mfg: ARCHITECT STAT; NR | per 10 ng/L | Results: adjusted | N: 90 RH: 0.9  95% CI: 0.75 to 1.08  p value: 0.25;  ref group: cont. variable | NR |
| Assa, 201311 | All cause mortality  subgroup data: predialysis cTnI |  | Assay: hs cTnI  Mfg: ARCHITECT STAT; NR | per 10 ng/L | Results: adjusted | N: 90 RH: 1  95% CI: 0.94 to 1.07  p value: 0.979;  ref group: cont. variable | NR |
| Assa, 201311 | One plus MACE  subgroup data: intra-HD change in cTnI levels |  | Assay: hs cTnI  Mfg: ARCHITECT STAT; NR | per 10 ng/L | Results: adjusted | N: 90 RH: 1.21  95% CI: 1.06 to 1.38  p value: 0.005;  ref group: cont. variable | NR |
| Assa, 201311 | One plus MACE  subgroup data: post-dialysis cTnI | NR | Assay: hs cTnI  Mfg: ARCHITECT STAT; NR | per 10 ng/L | Results: adjusted | N: 90 RH: 1.21  95% CI: 1.06 to 1.38  p value: 0.005;  ref group: cont. variable | NR |
| Assa, 201311 | One plus MACE  subgroup data: predialysis cTnI | NR | Assay: hs cTnI  Mfg: ARCHITECT STAT; NR | per 10 ng/L | Results: adjusted | N: 90 RH: 1.05  95% CI: 0.97 to 1.14  p value: 0.192;  ref group: cont. variable | NR |
| Aviles, 200212 | MACE < 1 year | Days: 30 | Assay: cTnT  Mfg: Roche; Elecsys | < ng/L< 0.03 mcg/L | Pts with event: 42 / 553 persons  Results: adjusted | OR: 2.7  95% CI: 1.9 to 3.8  p value: <0.001;  ref group: Grp3 | NR |
| Aviles, 200212 | MACE < 1 year | Days: 30 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.1 mcg/L | Pts with event: 70 / 783 persons  Results: adjusted | OR: 2.5  95% CI: 1.8 to 3.3  p value: <0.001;  ref group: Grp1 | NR |
| Aviles, 200212 | MACE < 1 year | Days: 30 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.03 mcg/L | Pts with event: 214 / 1180 persons  Results: adjusted | OR: 1 | NR |
| Aviles, 200212 | MACE < 1 year | Days: 30 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | Pts with event: 186 / 950 persons  Results: adjusted | OR: 1 | NR |
| Aviles, 200212 | MACE < 1 year | Days: 30 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.1 mcg/L | Pts with event: 20 / 805 persons  Results: adjusted | OR: 2.3  95% CI: 1.3 to 4.1  p value: 0.003;  ref group: Grp1 | NR |
| Aviles, 200212 | MACE < 1 year | Days: 30 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.03 mcg/L | Pts with event: 58 / 1117 persons  Results: adjusted | OR: 1 | NR |
| Aviles, 200212 | MACE < 1 year | Days: 30 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.03 mcg/L | Pts with event: 8 / 618 persons  Results: adjusted | OR: 4.8  95% CI: 2.3 to 10.4  p value: <0.001;  ref group: Grp3 | NR |
| Aviles, 200212 | MACE < 1 year | Days: 30 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | Pts with event: 46 / 930 persons  Results: adjusted | OR: 1 | NR |
| Aviles, 200212 | MACE < 1 year | Days: 30 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.03 mcg/L | Pts with event: 36 / 690 persons  Results: adjusted | OR: 2.4  95% CI: 1.6 to 3.6  p value: <0.001;  ref group: Grp3 | NR |
| Aviles, 200212 | MACE < 1 year | Days: 30 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.1 mcg/L | Pts with event: 60 / 917 persons  Results: adjusted | OR: 1.8  95% CI: 1.3 to 2.6  p value: <0.001;  ref group: Grp1 | NR |
| Aviles, 200212 | MACE < 1 year | Days: 30 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.03 mcg/L | Pts with event: 115 / 1113 persons  Results: adjusted | OR: 1 | NR |
| Aviles, 200212 | MACE < 1 year | Days: 30 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | Pts with event: 91 / 886 persons  Results: adjusted | OR: 1 | NR |
| Aviles, 200212 | MACE < 1 year | Days: 30 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.03 mcg/L | Pts with event: 22 / 660 persons  Results: adjusted | OR: 2.6  95% CI: 1.6 to 4.4  p value: <0.001;  ref group: Grp3 | NR |
| Aviles, 200212 | MACE < 1 year | Days: 30 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.1 mcg/L | % Pts with event: 47% / 883 persons  Results: adjusted | OR: 1.4  95% CI: 0.9 to 2.1  p value: 0.16;  ref group: Grp1 | NR |
| Aviles, 200212 | MACE < 1 year | Days: 30 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.03 mcg/L | Pts with event: 86 / 1102 persons  Results: adjusted | OR: 1 | NR |
| Aviles, 200212 | MACE < 1 year | Days: 30 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | Pts with event: 61 / 879 persons  Results: adjusted | OR: 1 | NR |
| Bagheri, 200913 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | <0.05 mg/L | % Pts with event: 24.2% / 46 persons  Results: unadjusted | NR | NR |
| Bagheri, 200913 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | >0.05 mg/L | 24% / 66 persons  Results: unadjusted | NR | NR |
| Bagheri, 200913 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | >0.05 mg/L | % Pts with event: 6.9% / 20 persons  Results: unadjusted | NR | NR |
| Beciani, 200315 | Cardio mortality/ Subs. MI/  revasc | Years: 1 | Assay: cTnI  Mfg: Dade Behring; opusplus | >0.15 ng/ml | Pts with event: 9  % Pts with event: 64% / 14 persons | NR | NR |
| Beciani, 200315 | Cardio mortality/  Subs. MI/  revasc | Years: 1 | Assay: cTnI  Mfg: Dade Behring; opusplus | <0.15 ng/ml | Pts with event: 7  % Pts with event: 9.7% / 72 persons | NR | NR |
| Beciani, 200315 | Cardio mortality/  Subs. MI/  revasc | Years: 1 | Assay: cTnI  Mfg: Dade Behring; opusplus | </>0.15 ng/ml | Pts with event: 3  % Pts with event: 20% / 15 persons | NR | NR |
| Boulier, 200417 | All-cause mortality | Days: 418 | Assay: cTnI  Mfg: Beckman; access | < 0.03 mcg/L | Results: adjusted | RR: 1 | NR |
| Boulier, 200417 | All-cause mortality | Days: 418 | Assay: cTnI  Mfg: Beckman; access | > 0.03 mcg/L | Results: adjusted | RR: 1.3  95% CI: 0.2 to 11.1;  ref group: Grp1 | NR |
| Boulier, 200417 | All-cause mortality | Days: 418 | Assay: cTnI  Mfg: Beckman; access | < 0.03 mcg/L | Results: adjusted | N: without CHD  RR: 1 | NR |
| Boulier, 200417 | All-cause mortality | Days: 418 | Assay: cTnI  Mfg: Beckman; access | > 0.03 mcg/L | Results: adjusted | N: without CHD  RR: 9.3  95% CI: 2.5 to 35;  ref group: Grp1 | NR |
| Boulier, 200417 | All-cause mortality | NR | Assay: cTnI  Mfg: Beckman; access | < 0.03 mcg/L | Results: adjusted | N: 143  RR: 1  p value: 0.0009 | NR |
| Boulier, 200417 | All-cause mortality | NR | Assay: cTnI  Mfg: Beckman; access | > 0.03 mcg/L | Results: adjusted | N: 48  RR: 3.9  95% CI: 1.7 to 8.6  p value: 0.0009; ref group: Grp1 | NR |
| Boulier, 200417 | Cardio mortality | NR | Assay: cTnI  Mfg: Beckman; access | < 0.03 mcg/L | Results: adjusted | N: 143  RR: 1  p value: 0.009 | NR |
| Boulier, 200417 | Cardio mortality | NR | Assay: cTnI  Mfg: Beckman; access | > 0.03 mcg/L | Results: adjusted | N: 48  RR: 5.4  95% CI: 1.5 to 19  p value: 0.009;  ref group: Grp1 | NR |
| Bozbas, 200418 | All-cause mortality | Days: 30 | Assay: cTnI  Mfg: DPC; immulite | > 2.3 mcg/L | Pts with event: 0 / 34 persons | NR | NR |
| Bozbas, 200418 | Subs. MI | Days: 30 | Assay: cTnI  Mfg: DPC; immulite | > 2.3 mcg/L | Pts with event: 0 / 34 persons | NR NR | NR |
| Brunet, 200819 | All-cause mortality | Years: 2.5 | Assay: cTnI  Mfg: Beckman; access | < 0.5 mcg/L | Pts with event: 41  % Pts with event: 40% / 103 persons | NR | NR |
| Brunet, 200819 | All-cause mortality | Years: 2.5 | Assay: cTnI  Mfg: Beckman; access | > 0.5 mcg/L | Pts with event: 0  % Pts with event: 0% / 2 persons | NR | NR |
| Brunet, 200819 | All-cause mortality | Years: 2.5 | Assay: cTnI  Mfg: Dade Behring; dimension | > 0.6 mcg/L | Pts with event: 1  % Pts with event: 33% / 3 persons | NR | NR |
| Brunet, 200819 | All-cause mortality | Years: 2.5 | Assay: cTnI  Mfg: Dade Behring; Troponin I Stat | < 0.6 mcg/L | Pts with event: 40  % Pts with event: 39% / 102 persons | NR | NR |
| Brunet, 200819 | All-cause mortality | Years: 2.5 | Assay: cTnI  Mfg: Roche; Elecsys | < 0.1 mcg/L | Pts with event: 24  % Pts with event: 31% / 77 persons | NR | NR |
| Brunet, 200819 | All-cause mortality | Years: 2.5 | Assay: cTnI  Mfg: Roche; Elecsys | > 0.1 mcg/L | Pts with event: 17  % Pts with event: 61% / 28 persons | NR | NR |
| Brunet, 200819 | All-cause mortality | Years: 2.5 | Assay: cTnI  Mfg: Beckman; access | < 0.06 mcg/L | Pts with event: 30  % Pts with event: 35% / 86 persons | NR | NR |
| Brunet, 200819 | All-cause mortality | Years: 2.5 | Assay: cTnI  Mfg: Beckman; access | > 0.06 mcg/L | Pts with event: 11  % Pts with event: 58% / 19 persons | NR | NR |
| Brunet, 200819 | All-cause mortality | Years: 2.5 | Assay: cTnI  Mfg: Dade Behring; dimension | < 0.14 mcg/L | Pts with event: 38  % Pts with event: 39% / 98 persons | NR | NR |
| Brunet, 200819 | All-cause mortality | Years: 2.5 | Assay: cTnI  Mfg: Dade Behring; dimension | > 0.14 mcg/L | Pts with event: 3  % Pts with event: 43% / 7 persons | NR | NR |
| Brunet, 200819 | All-cause mortality | Years: 2.5 | Assay: cTnI  Mfg: Roche; Elecsys | < 0.03 mcg/L | Pts with event: 11  % Pts with event: 27% / 41 persons | NR | NR |
| Brunet, 200819 | All-cause mortality | Years: 2.5 | Assay: cTnI  Mfg: Roche; Elecsys | > 0.03 mcg/L | Pts with event: 30  % Pts with event: 47% / 64 persons | NR | NR |
| Brunet, 200819 | MACE ≥ 1 year | Years: 2.5 | Assay: cTnI  Mfg: Beckman; access | < 0.5 mcg/L | Pts with event: 14  % Pts with event: 14% / 103 persons | NR | NR |
| Brunet, 200819 | MACE ≥ 1 year | Years: 2.5 | Assay: cTnI  Mfg: Beckman; access | > 0.5 mcg/L | Pts with event: 1  % Pts with event: 50% / 2 persons | NR | NR |
| Brunet, 200819 | MACE ≥ 1 year | Years: 2.5 | Assay: cTnI  Mfg: Roche; Elecsys | < 0.1 mcg/L | Pts with event: 4  % Pts with event: 5% / 77 persons | NR | NR |
| Brunet, 200819 | MACE ≥ 1 year | Years: 2.5 | Assay: cTnI  Mfg: Roche; Elecsys | > 0.1 mcg/L | Pts with event: 11  % Pts with event: 39% / 28 persons | NR | NR |
| Brunet, 200819 | MACE ≥ 1 year | Years: 2.5 | Assay: cTnI  Mfg: Dade Behring; dimension | < 0.14 mcg/L | Pts with event: 13  % Pts with event: 13% / 98 persons | NR | NR |
| Brunet, 200819 | MACE ≥ 1 year | Years: 2.5 | Assay: cTnI  Mfg: Dade Behring; dimension | < 0.6 mcg/L | Pts with event: 13  % Pts with event: 13% / 102 persons | NR | NR |
| Brunet, 200819 | MACE ≥ 1 year | Years: 2.5 | Assay: cTnI  Mfg: Dade Behring; dimension | > 0.14 mcg/L | Pts with event: 2  % Pts with event: 29% / 7 persons | NR | NR |
| Brunet, 200819 | MACE ≥ 1 year | Years: 2.5 | Assay: cTnI  Mfg: Dade Behring; dimension | > 0.6 mcg/L | Pts with event: 2  % Pts with event: 67% / 3 persons | NR | NR |
| Brunet, 200819 | MACE ≥ 1 year | Years: 2.5 | Assay: cTnI  Mfg: Roche; Elecsys | < 0.03 mcg/L | Pts with event: 2  % Pts with event: 5% / 41 persons | NR | NR |
| Brunet, 200819 | MACE ≥ 1 year | Years: 2.5 | Assay: cTnI  Mfg: Roche; Elecsys | > 0.03 mcg/L | Pts with event: 13  % Pts with event: 20% / 64 persons | NR | NR |
| Brunet, 200819 | MACE ≥ 1 year | Years: 2.5 | Assay: cTnI  Mfg: Beckman; access | < 0.06 mcg/L | Pts with event: 10  % Pts with event: 12% / 86 persons | NR | NR |
| Brunet, 200819 | MACE ≥ 1 year | Years: 2.5 | Assay: cTnI  Mfg: Beckman; access | > 0.06 mcg/L | Pts with event: 5  % Pts with event: 26% / 19 persons | NR | NR |
| Bueti, 200620 | MACE < 1 year-revasc | NR | Assay: cTnI | < 0.1 ng/L | NR | NR | NR |
| Bueti, 200620 | MACE < 1 year-revasc | NR | Assay: cTnI | > 0.1 ng/L | NR | OR: 10.7  95% CI: 3.6 to 31;  ref group: < 0.1 ng/L | NR |
| Bueti, 200620 | MACE < 1 year-revasc | Days: 30 | Assay: cTnI  Mfg: Bayer; other; Immuno 1 | < 0.1 ng/L | Results: unadjusted | LR: 0.32  95% CI: 0.16 to 0.63 | NR |
| Bueti, 200620 | MACE < 1 year-revasc | Days: 30 | Assay: cTnI  Mfg: Bayer; other; Immuno 1 | > 0.1 ng/L < 0.3 ng/L | Results: unadjusted | LR: 0.7  95% CI: 0.09 to 5.5 | NR |
| Bueti, 200620 | MACE < 1 year-Revascularization | Days: 30 | Assay: cTnI  Mfg: Bayer; other; Immuno 1 | > 0.3 ng/L < 1 ng/L | Results: unadjusted | Likelihood ratio: 4.33  95% CI: 1.04 to 18 | NR |
| Bueti, 200620 | MACE < 1 year-Revascularization | Days: 30 | Assay: cTnI  Mfg: Bayer; other; Immuno 1 | > 1 ng/L < 2 ng/L | Results: unadjusted | Likelihood ratio: 5.77  95% CI: 0.85 to 39 | NR |
| Bueti, 200620 | MACE < 1 year-Revascularization | Days: 30 | Assay: cTnI  Mfg: Bayer; other; Immuno 1 | > 2 ng/L | Results: unadjusted | Likelihood ratio: 11.7  95% CI: 4.4 to 31 | NR |
| Bueti, 200620 | MACE < 1 year-Revascularization | Days: 30 | NR | NR | Results: unadjusted | NR | NR |
| Bueti, 200620 | MACE < 1 year-Revascularization | Days: 30 | Assay: cTnI  Mfg: Bayer; other; Immuno 1 | < 0.1 ng/L | Results: unadjusted | OR: 1 | NR |
| Bueti, 200620 | MACE < 1 year-Revascularization | Days: 30 | Assay: cTnI  Mfg: Bayer; other; Immuno 1 | > 0.1 ng/L | Results: unadjusted | OR: 15.2  95% CI: 5.26 to 43.6  p value: 4e-007;  ref group: Grp1 | NR |
| Chew, 200821 | All-cause mortality | NR | Assay: cTnT  Mfg: NR; NR | < 0.1 mcg/L | NR/ 106 persons  Results: unadjusted | NR | NR |
| Chew, 200821 | All-cause mortality | NR | Assay: cTnT  Mfg: NR; NR | > 0.1 mcg/L | NR/ 121 persons  Results: unadjusted | NR | NR |
| Choy, 200322 | All-cause mortality | NR | Assay: cTnI  Mfg: Dade Behring | < 0.5 mcg/L | Pts with event: 11 / 96 persons | NR | NR |
| Choy, 200322 | All-cause mortality | NR | Assay: cTnI  Mfg: Dade Behring | > 0.5 mcg/L | Pts with event: 1 / 17 persons | NR | NR |
| Choy, 200322 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche | > 0.1 mcg/L | Pts with event: 10 / 48 persons | NR | NR |
| Choy, 200322 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; NR | < 0.1 mcg/L | Pts with event: 3 / 65 persons | N: 48  OR: 13.6  95% CI: 2.5 to 73.2  p value: 0.002;  ref group: Grp1 | NR |
| Choy, 200322 | All-cause mortality | NR | Assay: NR  Mfg: Roche; NR | NR | Pts with event: 13 / 113 persons | N: 65  OR: 1 | NR |
| Choy, 200322 | Subs. MI | NR | Assay: cTnI  Mfg: Dade Behring; NR | < 0.5 mcg/L | Pts with event: 0 / 96 persons | NR | NR |
| Choy, 200322 | Subs. MI | NR | Assay: cTnI  Mfg: Dade Behring; NR | > 0.5 mcg/L | Pts with event: 1 / 17 persons | NR | NR |
| Choy, 200322 | Subs. MI | NR | Assay: cTnT  Mfg: Roche; NR | > 0.1 mcg/L | Pts with event: 0 / 48 persons | NR | NR |
| Choy, 200322 | Subs. MI | NR | Assay: cTnT  Mfg: Roche; NR | > 0.1 mcg/L | Pts with event: 0 / 65 persons | NR | NR |
| Chrysochou, 200923 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | <0.03 ng/mL | Results: unadjusted | N: 71  RH: 1 | NR |
| Chrysochou, 200923 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | >0.03 ng/mL | Results: unadjusted | N: 11  RH: 3.9  95% CI: 1.8 to 8.5  p value: 0.001;  ref group: Grp1 | NR |
| Chrysochou, 200923 | Cardio mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | <0.03 ng/mL | Pts with event: 11 / 71 persons  Results: unadjusted | NR | NR |
| Chrysochou, 200923 | Cardio mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | >0.03 ng/mL | No. of events: 4 / 11 persons  Results: unadjusted | NR | NR |
| Claes, 201024 | MACE < 1 year | Weeks: 2 | NR | NR | NR | NR | AUC: 0.85  Sens: 0.55  Spec: 0.98 |
| Claes, 201024 | MACE < 1 year | Weeks: 2 | Assay: cTnI  Mfg: other  Mfg: Siemens; Heterogenous Immunoassay | < 0.02 mcg/L | NR | NR | AUC: 0.85  Sens: 0.55  Spec: 0.98 |
| Claes, 201024 | MACE < 1 year | Weeks: 2 | Assay: cTnI  Mfg: other  Mfg: Siemens; Heterogenous Immunoassay | > 0.02 mcg/L< 0.06 mcg/L | NR | NR | AUC: 0.85  Sens: 0.55  Spec: 0.98 |
| Claes, 201024 | MACE < 1 year | Weeks: 2 | Assay: cTnI  Mfg: other  Mfg: Siemens; Heterogenous Immunoassay | > 0.06 mcg/L< 0.13 mcg/L | NR | NR | AUC: 0.85  Sens: 0.55  Spec: 0.98 |
| Claes, 201024 | MACE < 1 year | Weeks: 2 | Assay: cTnI  Mfg: other  Mfg: Siemens; Heterogenous Immunoassay | > 0.13 mcg/L | NR | NR | AUC: 0.85  Sens: 0.55  Spec: 0.98 |
| Codognotto, 201025 | All-cause mortality | Years: 3 | Assay: cTnI  Mfg: other  Mfg: Siemans; lithium-heparin plasma | < 0.15 mcg/L | % Pts with event: 20.6%  Results: adjusted | NR | NR |
| Codognotto, 201025 | All-cause mortality | Years: 3 | Assay: cTnI  Mfg: other  Mfg: Siemans; lithium-heparin plasma | > 0.15 mcg/L | % Pts with event: 43.3%  Results: adjusted | NR | NR |
| Codognotto, 201025 | All-cause mortality | Years: 3 | Assay: cTnT  Mfg: Roche; NR | < 0.01 mcg/L | % Pts with event: 13.2%  Results: adjusted | NR | NR |
| Codognotto, 201025 | All-cause mortality | Years: 3 | Assay: cTnT  Mfg: Roche; NR | > 0.01 mcg/L | % Pts with event: 40.2%  Results: adjusted | NR | NR |
| Connolly, 200826 | All-cause mortality | Days: 1626 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.03 mcg/L | Pts with event: 49 / 351 persons  Results: adjusted | N: 351  Exponent Beta: 1 | NR |
| Connolly, 200826 | All-cause mortality | Days: 1626 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.03 mcg/L | Pts with event: 12 / 21 persons  Results: adjusted | N: 21  Exponent Beta: 2.669  95% CI: 1.201 to 6.056  p value: <0.016;  ref group: Grp1 | NR |
| Connolly, 200826 | Cardio mortality | Days: 1626 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.03 mcg/L | Pts with event: 17 / 351 persons  Results: unadjusted | NR | NR |
| Connolly, 200826 | Cardio mortality | Days: 1626 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.03 mcg/L | Pts with event: 7 / 21 persons  Results: unadjusted | NR | NR |
| Conway, 200527 | MACE ≥ 1 year-MACE < 1 year-Other composite (unstable angina) |  | Assay: cTnT  Mfg: Roche; other; ECLIA | > 0.03 mcg/L< 0.1 mcg/L | Pts with event: 9 / 22 persons  Results: unadjusted | NR | NR |
| Conway, 200527 | MACE ≥ 1 year-MACE < 1 year-Other composite (unstable angina) |  | Assay: cTnT  Mfg: Roche; other; ECLIA | < 0.03 mcg/L | Pts with event: 4 / 40 persons  Results: unadjusted | NR | NR |
| Conway, 200527 | MACE ≥ 1 year-MACE < 1 year-Other composite (unstable angina) |  | Assay: cTnT  Mfg: Roche; other; ECLIA | > 0.1 mcg/L | Pts with event: 7 / 13 persons  Results: unadjusted | NR | NR |
| Deegan, 200128 | All-cause mortality |  | NR | NR | Results: unadjusted | NR | AUC: 0.857  95% CI: 0.755 to 0.928  Sens: 0.6  Spec: 0.85 |
| Deegan, 200128 | All-cause mortality |  | Assay: cTnT  Mfg: other  Mfg: Boehringer Mannheim; Elecsys | < 0.1 mcg/L | Pts with event: 7  % Pts with event: 15% / 53 persons  Results: unadjusted | N: 53  Ref | AUC: 0.857  95% CI: 0.755 to 0.928  Sens: 0.6  Spec: 0.85 |
| Deegan, 200128 | All-cause mortality |  | Assay: cTnT  Mfg: other  Mfg: Boehringer Mannheim; Elecsys | > 0.1 mcg/L | Pts with event: 13  % Pts with event: 65% / 20 persons  Results: unadjusted | N: 20  RH: 4.1;  ref group: Grp1 | AUC: 0.857  95% CI: 0.755 to 0.928  Sens: 0.6  Spec: 0.85 |
| Deegan, 200128 | Cardio mortality |  | Assay: cTnT  Mfg: other  Mfg: Boehringer Mannheim; Elecsys | < 0.1 mcg/L | Pts with event: 5 / 53 persons  Results: unadjusted | NR | NR |
| Deegan, 200128 | Cardio mortality | NR | Assay: cTnT  Mfg: other  Mfg: Boehringer Mannheim; Elecsys | > 0.1 mcg/L | Pts with event: 7 / 20 persons  Results: unadjusted | NR | NR |
| deFilippi, 200329 | All-cause mortality | Days: 827 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.029 mcg/L | Pts with event: 16  % Pts with event: 28% / 57 persons  Results: adjusted | N: 57  HR: NR | NR |
| deFilippi, 200329 | All-cause mortality | Days: 827 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.117 mcg/L | Pts with event: 36  % Pts with event: 65% / 55 persons  Results: adjusted | N: 55  HR: 2.8  95% CI: 5 to 1.5  p value: 0.001; ref group: Grp1 | NR |
| deFilippi, 200329 | All-cause mortality | Days: 827 | Assay: cTnT  Mfg: Roche; Elecsys | 0.029-0.064 ng/mL | Pts with event: 30  % Pts with event: 54% / 56 persons  Results: adjusted | N: 56  HR: 1.6  95% CI: 3 to 0.9  p value: 0.14;  ref group: Grp1 | NR |
| deFilippi, 200329 | All-cause mortality | Days: 827 | Assay: cTnT  Mfg: Roche; Elecsys | 0.065-0.116 ng/mL | Pts with event: 34  % Pts with event: 62% / 55 persons  Results: adjusted | N: 55  HR: 2.3  95% CI: 4.2 to 1.3  p value: 0.006;  ref group: Grp1 | NR |
| deFilippi, 201230 | All-cause mortality | Years: 4.8 | Assay: hscTnI  Mfg: other  Mfg: Siemens; other; Dimension Vista 1500 | < 11.6 ng/L | NR | RH: 6.34  95% CI: 2.18 to 18.5;  ref group: Grp1 | NR |
| deFilippi, 201230 | All-cause mortality | Years: 4.8 | Assay: hscTnI  Mfg: other  Mfg: Siemens; other; Dimension Vista 1500 | < 4 ng/L | NR | RH: 1 | NR |
| deFilippi, 201230 | All-cause mortality | Years: 4.8 | Assay: hscTnI  Mfg: other  Mfg: Siemens; other; Dimension Vista 1500 | > 4 ng/L < 11.6 ng/L | NR | RH: 2.07  95% CI: 0.62 to 6.88;  ref group: Grp1 | NR |
| deFilippi, 201230 | All-cause mortality | Years: 4.8 | Assay: hscTnI  Mfg: Roche; Elecsys | > 13.2 ng/L< 24.3 mcg/L | NR | RH: 1.19  95% CI: 0.36 to 3.9;  ref group: Grp1 | NR |
| deFilippi, 201230 | All-cause mortality | Years: 4.8 | Assay: hscTnT  Mfg: Roche; Elecsys | < 13.2 ng/L | NR | RH: 1 | NR |
| deFilippi, 201230 | All-cause mortality | Years: 4.8 | Assay: hscTnT  Mfg: Roche; Elecsys | > 24.4 ng/L | NR | RH: 5.2  95% CI: 13.73 to 1.97; ref group: Grp1 | NR |
| Dierkes, 200031 | All-cause mortality | Years: 2 |  | < 0.04 mcg/L | Pts with event: 0 / 17 persons  Results: adjusted | NR | NR |
| Dierkes, 200031 | All-cause mortality | Years: 2 | Assay: cTnT  Mfg: Roche; NR | > 0.04 mcg/L | Pts with event: 18 / 40 persons  Results: adjusted | NR | NR |
| Dierkes, 200031 | All-cause mortality | Years: 2 | Assay: cTnT  Mfg: Roche; NR | > 0.1 mcg/L | Pts with event: 10 / 12 persons  Results: adjusted | RH: 7.31  95% CI: 1.85 to 28.83 | NR |
| Duman, 200532 | All-cause mortality | NR | Assay: cTnI  Mfg: other  Mfg: Diagnostic Product corp; immulite | > 0.06 mcg/L | No. of events: 3 / 4 persons  Results: adjusted | NR | NR |
| Duman, 200532 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.01 mcg/L | No. of events: 10 / 15 persons  Results: adjusted | N: 36  OR: 1  SE: NR | NR |
| Duman, 200532 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.035 mcg/L | Pts with event:  No. of events: 17 / 29 persons  Results: adjusted | N: 29  OR: 4.31  SE: 0.67  95% CI: 1.16 to 16.04  p value: 0.02;  ref group: Grp1 | NR |
| Duman, 200532 | Cardio mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.01 mcg/L | No. of events: 16 / 23 persons  Results: unadjusted | N: 36  OR: 1  SE: NR | NR |
| Duman, 200532 | Cardio mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.035 mcg/L | No. of events: 16 / 23 persons  Results: unadjusted | N: 29  OR: 8.94  SE: 0.71  95% CI: 2.23 to 35.88  p value: 0.002;  ref group: Grp1 | NR |
| Farkouh, 200333 | All-cause mortality | NR | Assay: cTnI  Mfg: Dade Behring; other; Stratus-II enzyme immunoassay | < 1 mcg/L | Pts with event: 15 / 127 persons  Results: adjusted | N: 127  RH: 1 | NR |
| Farkouh, 200333 | All-cause mortality | NR | Assay: cTnI  Mfg: Dade Behring; other; Stratus-II enzyme immunoassay | > 1 mcg/L | Pts with event: 4 / 10 persons  Results: adjusted | N: 10  RH: 9.6  95% CI: 2.8 to 33  p value: <0.01;  ref group: Grp1 | NR |
| Feringa, 200635 | All-cause mortality | Years: 4 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.03 ng/L | Results: adjusted | RH: 1 | NR |
| Feringa, 200635 | All-cause mortality | Years: 4 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.03 ng/L < 0.09 ng/L | Results: adjusted | RH: 4.27  95% CI: 1.75 to 10.4  p value: <0.001;  ref group: Grp1 | NR |
| Feringa, 200635 | All-cause mortality | Years: 4 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 ng/L | Results: adjusted | RH: 5.54  95% CI: 2.92 to 10.52  p value: <0.001;  ref group: Grp1 | NR |
| Feringa, 200635 | MACE ≥ 1 year-MACE < 1 year | Years: 4 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.03 ng/L | Results: adjusted | RH: 1 | NR |
| Feringa, 200635 | MACE ≥ 1 year-MACE < 1 year | Years: 4 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.03 ng/L < 0.09 ng/L | Results: adjusted | RH: 8.09  95% CI: 2.72 to 24.05  p value: <0.001;  ref group: Grp1 | NR |
| Feringa, 200635 | MACE ≥ 1 year-MACE < 1 year | Years: 4 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 ng/L | Results: adjusted | RH: 7.05  95% CI: 3.44 to 14.47  p value: <0.001;  ref group: Grp1 | NR |
| Fernandez-Reyes, 200436 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.01 mcg/L | Results: unadjusted | N: 53  RR: 1.07  Cox hazard model:  95% CI: 1.03 to 1.12  p value: 0.01 | NR |
| Fernandez-Reyes, 200436 | Other composite (heart failure) | Years: 2.5 | Assay: cTnT  Mfg: Roche; Elecsys | <0.04 ng/mL | Pts with event: 2 / 23 persons | NR | NR |
| Fernandez-Reyes, 200436 | Other composite (heart failure) | Years: 2.5 | Assay: cTnT  Mfg: Roche; Elecsys | >0.04 ng/mL | Pts with event: 1 / 12 persons | NR | NR |
| Fernandez-Reyes, 200436 | Other composite (heart failure) | Years: 2.5 | Assay: cTnT  Mfg: Roche; Elecsys | 0.04-0.1 ng/mL | Pts with event: 1 / 11 persons | NR | NR |
| Fernandez-Reyes, 200436 | Other composite (ischemic heart disease) | Years: 2.5 | NR | NR | Pts with event: 5 / 16 persons | NR | NR |
| Fernandez-Reyes, 200436 | Other composite (ischemic heart disease) | Years: 2.5 | Assay: cTnT  Mfg: Roche; Elecsys | <0.04 ng/mL | Pts with event: 0 / 23 persons | NR | NR |
| Fernandez-Reyes, 200436 | Other composite (ischemic heart disease) | Years: 2.5 | Assay: cTnT  Mfg: Roche; Elecsys | >0.04 ng/mL | Pts with event: 3 / 12 persons | NR | NR |
| Fernandez-Reyes, 200436 | Other composite (ischemic heart disease) | Years: 2.5 | Assay: cTnT  Mfg: Roche; Elecsys | 0.04-0.1 ng/mL | Pts with event: 1 / 11 persons | NR | NR |
| Flores, 200637 | Subs. MI | Followup NR | Assay: cTnI  Mfg: Beckman; access | <0.05 ng/mL | Pts with event: 0 / 47 persons  Results: unadjusted | NR | NR |
| Flores, 200637 | Subs. MI | Followup NR | Assay: cTnI  Mfg: Beckman; access | > 0.05 ng/mL | Pts with event: 14 / 47 persons  Results: unadjusted | NR | NR |
| Flores, 200637 | Subs. MI | Followup NR | Assay: cTnI  Mfg: Beckman; access | >0.5 ng/mL | Pts with event: 33 / 47 persons  Results: unadjusted | NR | NR |
| Gaiki, 201239 | All-cause mortality | Years: 2 | Assay: hscTnI  Mfg: other  Mfg: Ortho clinical diagnostics; Vitro ES | <0.035 ng/mL | No. of events: 6 / 25 persons  Results: unadjusted | NR | NR |
| Gaiki, 201239 | All-cause mortality | Years: 2 | Assay: hscTnI  Mfg: other  Mfg: Ortho clinical diagnostics; Vitro ES | >0.035 ng/mL | No. of events: 8 / 25 persons  Results: unadjusted | NR | NR |
| Gaiki, 201239 | Other composite (composite of ACS, revasc, cardiac arrest, sudden death) | Years: 2 | Assay: hscTnI  Mfg: other  Mfg: Ortho clinical diagnostics; Vitro ES | <0.035 | No. of events: 0 / 25 persons  Results: unadjusted | NR | NR |
| Gaiki, 201239 | Other composite (Composite of ACS, revasc, cardiac arrest, sudden death) | Years: 2 | Assay: hscTnI  Mfg: other  Mfg: Ortho clinical diagnostics; Vitro ES | >0.035 ng/mL | No. of events: 6 / 25 persons  Results: unadjusted | NR | NR |
| Geerse, 201240 | All-cause mortality | NR | Assay: cTnI  Mfg: other  Mfg: Siemens medical solutions diagnostics; other; Advia Centaur | < 0.01 mcg/L | % Pts with event: 10.1% / 59 persons  Results: adjusted | N: 59  RH: 1 | NR |
| Geerse, 201240 | All-cause mortality | NR | Assay: cTnI  Mfg: other  Mfg: Siemens medicals solutions diagnostics; other; Advia Centaur | > 0.01 mcg/L< 0.05 mcg/L | % Pts with event: 36.6% / 94 persons  Results: adjusted | N: 94  RH: 2.55  95% CI: 1.05 to 6.21  p value: 0.039;  ref group: Grp1 | NR |
| Geerse, 201240 | All-cause mortality | NR | Assay: cTnI  Mfg: other  Mfg: Siemens medical solutions diagnostics; other; Advia Centaur | > 0.05 mcg/L< 0.1 mcg/L | % Pts with event: 50.4% / 28 persons  Results: adjusted | N: 28  RH: 3.57  95% CI: 1.31 to 9.71  p value: 0.013;  ref group: Grp1 | NR |
| Geerse, 201240 | All-cause mortality | NR | Assay: cTnI  Mfg: other  Mfg: Siemens medical solutions diagnostics; other; Advia Centaur | > 0.1 mcg/L | % Pts with event: 72.3% / 25 persons  Results: adjusted | N: 25  RH: 6.35  95% CI: 2.43 to 16.49  p value: <0.001;  ref group: Grp1 | NR |
| Geerse, 201240 | Cardio mortality | NR | NR | < 0.01 mcg/L | % Pts with event: 5.05% / 59 persons | NR | NR |
| Geerse, 201240 | Cardio mortality | NR | NR | > 0.01 mcg/L< 0.05 mcg/L | % Pts with event: 21.2% / 94 persons | NR | NR |
| Geerse, 201240 | Cardio mortality | NR | NR | > 0.05 mcg/L< 0.1 mcg/L | % Pts with event: 32.3% / 28 persons | NR | NR |
| Geerse, 201240 | Cardio mortality | NR | NR | > 0.1 mcg/L | % Pts with event: 56.2% / 25 persons | NR | NR |
| Goicoechea, 200441 | MACE ≥ 1 year-MACE < 1 year-Revascularization | NR | NR |  | Results: unadjusted | NR | NR |
| Goicoechea, 200441 | MACE ≥ 1 year-MACE < 1 year-revasc | NR | Assay: cTnT  Mfg: Roche; Elecsys | < 0.01 ng/L | Results: unadjusted | N: 156  RH: 1  p value: 0 | NR |
| Goicoechea, 200441 | MACE ≥ 1 year-MACE < 1 year-revasc | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.01 ng/L | Results: unadjusted | N: 20  RH: 12.34  95% CI: 4.91 to 31.02  p value: 0;  ref group: Grp1 | NR |
| Gruberg, 200242 | All-cause mortality | NR | Assay: cTnI  Mfg: Beckman; other; Chemiluscent immunoenzymatic assay | < 0.15 mcg/L | % Pts with event: 9.9% / 66 persons  Results: adjusted | OR: NR | NR |
| Gruberg, 200242 | All-cause mortality | NR | Assay: cTnI  Mfg: Beckman; other; Chemiluscent immunoenzymatic assay | > 0.15 mcg/L | % Pts with event: 28% / 50 persons  Results: adjusted | OR: 2.26  95% CI: 1.07 to 4.77  p value: 0.03;  ref group: Grp1 | NR |
| Gruberg, 200242 | MACE ≥ 1 year | NR | Assay: cTnI  Mfg: Beckman; other; Chemiluscent Immunoenzymatic Assay | < 0.15 mcg/L | % Pts with event: 30.1% / 66 persons | NR | NR |
| Gruberg, 200242 | MACE ≥ 1 year | NR | Assay: cTnI  Mfg: Beckman; other; Chemiluscent immunoenzymatic assay | > 0.15 mcg/L | % Pts with event: 40.3% / 50 persons | NR | NR |
| Gruberg, 200242 | Revascularization | NR | Assay: cTnI  Mfg: Beckman; other; Chemiluscent Immunoenzymatic Assay | < 0.15 mcg/L | % Pts with event: 20% / 66 persons | NR | NR |
| Gruberg, 200242 | Revascularization | NR | Assay: cTnI  Mfg: Beckman; other; Chemiluscent Immunoenzymatic Assay | > 0.15 mcg/L | % Pts with event: 19% / 50 persons | NR | NR |
| Gruberg, 200242 | Subs. MI | NR | Assay: cTnI  Mfg: Beckman; other; Chemiluscent Immunoenzymatic Assay | < 0.15 mcg/L | % Pts with event: 13.8% / 66 persons | NR | NR |
| Gruberg, 200242 | Subs. MI | NR | Assay: cTnI  Mfg: Beckman; other; Chemiluscent Immunoenzymatic Assay | > 0.15 mcg/L | % Pts with event: 25% / 50 persons | NR | NR |
| Hallen, 201144 | All-cause mortality | Days: 926 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.01 mcg/L | Pts with event: 43 / 64 persons  Results: adjusted | N: 64  RH: 3.2  95% CI: 1.2 to 8.5  p value: <0.017;  ref group: Grp1 | NR |
| Hallen, 201144 | All-cause mortality | Days: 926 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.01 mcg/L | Pts with event: 7 / 43 persons  Results: adjusted | N: 43  RH: 1 | NR |
| Han, 200545 | Other composite (ACE) | NR | NR | NR | Results: unadjusted | NR | AUC: 0.6  95% CI: 0.45 to 0.74  Sens: 27  Spec: 96 |
| Han, 200545 | Other composite (ACE) | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.01 mcg/L | Results: unadjusted | NR | AUC: 0.6  95% CI: 0.45 to 0.74  Sens: 27  Spec: 96 |
| Han, 200946 | Other composite (cardiac events) | Years: 3 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.1 mcg/L | Pts with event: 4 / 86 persons  Results: adjusted | N: 86  RH: 1 | NR |
| Han, 200946 | Other composite (cardiac events) | Years: 3 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | Pts with event: 9 / 21 persons  Results: adjusted | N: 21  RH: 5.89  95% CI: 1.24 to 28  p value: <0.05; ref group: Grp1 | NR |
| Hasegawa, 201247 | Other composite (cardiac events) | NR | Assay: hscTnT  Mfg: Roche; NR | <9 pg/mL | % Pts with event: 0.88% / 113 persons  Results: adjusted | N: 113  RH: 1 | NR |
| Hasegawa, 201247 | Other composite (cardiac events) | NR | Assay: hscTnT  Mfg: Roche; NR | >33 pg/mL | % Pts with event: 41.4% / 108 persons  Results: adjusted | N: 108  RH: 6.18  95% CI: 1.38 to 27.69; ref group: Grp1 | NR |
| Hasegawa, 201247 | Other composite (cardiac events) | NR | Assay: hscTnT  Mfg: Roche; NR | 10-18 pg/mL | % Pts with event: 11.5% / 111 persons  Results: adjusted | N: 111  RH: 2.54  95% CI: 0.54 to 11.93; ref group: Grp1 | NR |
| Hasegawa, 201247 | Other composite (cardiac events) | NR | Assay: hscTnT  Mfg: Roche; NR | 19-32 pg/mL | % Pts with event: 19% / 110 persons  Results: adjusted | N: 110  RH: 3  95% CI: 0.66 to 13.7;  ref group: Grp1 | NR |
| Havekes, 200648 | All-cause mortality | Followup NR | Assay: cTnT  Mfg: Roche; NR | > 0.05 mcg/L< 0.1 mcg/L | Results: adjusted | N: 188  RH: 1.2  95% CI: 0.9 to 1.7;  ref group: Grp1 | NR |
| Havekes, 200648 | All-cause mortality | Followup NR | Assay: cTnT  Mfg: Roche; NR | > 0.1 mcg/L | Results: adjusted | N: 93  RH: 2.2  95% CI: 1.5 to 3.3;  ref group: Grp1 | NR |
| Havekes, 200648 | All-cause mortality | Followup NR | Assay: cTnT  Mfg: Roche; other; 3rd generation immunochemical test | < 0.04 mcg/L | Results: adjusted | N: 566  RH: 1 | NR |
| Havekes, 200648 | Cardio mortality | Followup NR | Assay: cTnT  Mfg: Roche; NR | < 0.04 mcg/L | Results: adjusted | N: 566  RH: 1 | NR |
| Havekes, 200648 | Cardio mortality | Followup NR | Assay: cTnT  Mfg: Roche; NR | > 0.04 mcg/L< 0.1 mcg/L | Results: adjusted | N: 188  RH: 1  95% CI: 0.6 to 1.7; ref group: Grp1 | NR |
| Havekes, 200648 | Cardio mortality | Followup NR | Assay: cTnT  Mfg: Roche; NR | > 0.1 mcg/L | Results: adjusted | N: 93  RH: 1.9  95% CI: 0.9 to 3.7; ref group: Grp1 | NR |
| Heeschen, 200049 | MACE < 1 year-revasc | Days: 30 | Assay: cTnI  Mfg: other  Mfg: Abbott; other; AxSYM | < 1 mcg/L | Pts with event: 0 / 24 persons  Results: unadjusted | NR | NR |
| Heeschen, 200049 | MACE < 1 year-revasc | Days: 30 | Assay: cTnI  Mfg: other  Mfg: Abbott; other; AxSYM | > 1 mcg/L | Pts with event: 0 / 2 persons  Results: unadjusted | NR | NR |
| Heeschen, 200049 | MACE < 1 year-revasc | Days: 30 | Assay: cTnT  Mfg: other  Mfg: Boehringer; Elecsys | < 0.06 mcg/L | Pts with event: 0 / 12 persons  Results: unadjusted | NR | NR |
| Heeschen, 200049 | MACE < 1 year-revasc | Days: 30 | Assay: NR  Mfg: other  Mfg: Boehringer; Elecsys | > 0.06 mcg/L | Pts with event: 0 / 14 persons  Results: unadjusted | NR | NR |
| Helleskov Madsen, 200850 | All-cause mortality | Days: 970 | Assay: cTnI  Mfg: Beckman; access | < 0.06 mcg/L | Pts with event: 28 / 97 persons  Results: adjusted | RR: 1 | NR |
| Helleskov Madsen, 200850 | All-cause mortality | Days: 970 | Assay: cTnI  Mfg: Beckman; access | > 0.06 mcg/L | Pts with event: 6 / 12 persons  Results: adjusted | RR: 1.9  95% CI: 0.6 to 6.4;  ref group: Grp3 | NR |
| Helleskov Madsen, 200850 | All-cause mortality | Days: 970 | Assay: cTnI  Mfg: Dade Behring; dimension | < 0.14 mcg/L | Pts with event: 30 / 101 persons  Results: adjusted | RR: 1 | NR |
| Helleskov Madsen, 200850 | All-cause mortality | Days: 970 | Assay: cTnI  Mfg: Dade Behring; dimension | > 0.14 mcg/L | Pts with event: 4 / 8 persons  Results: adjusted | RR: 2  95% CI: 0.7 to 5.8  p value: ns;  ref group: Grp3 | NR |
| Helleskov Madsen, 200850 | All-cause mortality | Days: 970 | Assay: cTnI  Mfg: other  Mfg: TOSOH; AIA-600II | < 0.1 mcg/L | Pts with event: 32 / 107 persons  Results: adjusted | RR: 1 | NR |
| Helleskov Madsen, 200850 | All-cause mortality | Days: 970 | Assay: cTnI  Mfg: other  Mfg: TOSOH; AIA-600II | > 0.1 mcg/L | Pts with event: 2 / 2 persons  Results: adjusted | RR: 2.8  95% CI: 0.6 to 13.4  p value: ns;  ref group: Grp1 | NR |
| Helleskov Madsen, 200850 | All-cause mortality | Days: 970 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.03 mcg/L | Pts with event: 5 / 52 persons  Results: adjusted | RR: 1 | NR |
| Helleskov Madsen, 200850 | All-cause mortality | Days: 970 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.03 mcg/L | Pts with event: 29 / 57 persons  Results: adjusted | RR: 7.7  95% CI: 2.7 to 21.9;  ref group: Grp1 | NR |
| Hickman, 200951 | All-cause mortality | NR | Assay: cTnI  Mfg: other  Mfg: Abbott; Architect ci8200 |  | Results: unadjusted | OR: ref | NR |
| Hickman, 200951 | All-cause mortality | NR | Assay: cTnI  Mfg: other  Mfg: Abbott; Architect ci8200 | < 0.01 mcg/L | Pts with event: 1 / 34 persons  Results: unadjusted | NR | NR |
| Hickman, 200951 | All-cause mortality | NR | Assay: cTnI  Mfg: other  Mfg: Abbott; Architect ci8200 | < 0.043 mcg/L | Results: unadjusted | N: 104  OR: ref | NR |
| Hickman, 200951 | All-cause mortality | NR | Assay: cTnI  Mfg: other  Mfg: Abbott; Architect ci8200 | > 0.011 mcg/L< 0.02 mcg/L | Pts with event: 3 / 35 persons  Results: unadjusted | NR | NR |
| Hickman, 200951 | All-cause mortality | NR | Assay: cTnI  Mfg: other  Mfg: Abbott; Architect ci8200 | > 0.021 mcg/L< 0.043 mcg/L | Pts with event: 10 / 35 persons  Results: unadjusted | NR | NR NR |
| Hickman, 200951 | All-cause mortality | NR | Assay: cTnI  Mfg: other  Mfg: Abbott; Architect ci8200 | > 0.043 mcg/L | Results: unadjusted | N: 34  OR: 4.5  95% CI: 1.86 to 10.91  p value: <0.001;  ref group: Grp2 | NR |
| Hickman, 200951 | All-cause mortality | NR | Assay: cTnI  Mfg: other  Mfg: Abbott; Architect ci8200 | > 0.043 mcg/L | Pts with event: 14 / 34 persons  Results: unadjusted | NR | NR |
| Hickman, 200951 | All-cause mortality | NR | Assay: cTnI  Mfg: other  Mfg: Abbott; Architect ci8200 | detectable | Results: unadjusted | OR: 6.37  95% CI: 0.82 to 49.58  p value: 0.087;  ref group: Grp2 | NR |
| Hickman, 200951 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | < 0.01 mcg/L | Pts with event: 1 / 35 persons  Results: unadjusted | NR | NR |
| Hickman, 200951 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | < 0.098 mcg/L | Results: unadjusted | N: 107  OR: ref | NR |
| Hickman, 200951 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.011 mcg/L< 0.042 mcg/L | Pts with event: 6 / 36 persons  Results: unadjusted | NR | NR |
| Hickman, 200951 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.043 mcg/L< 0.097 mcg/L | Pts with event: 7 / 36 persons  Results: unadjusted | NR | NR |
| Hickman, 200951 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.098 mcg/L | Results: unadjusted | N: 36  OR: 4.23  95% CI: 1.76 to 10.14  p value: 0.001;  ref group: Grp2 | NR |
| Hickman, 200951 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.098 mcg/L | Pts with event: 14 / 36 persons  Results: unadjusted | NR | NR |
| Hickman, 200951 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | detectable | Results: unadjusted | OR: 11.33  95% CI: 1.48 to 86.79  p value: 0.004;  ref group: Grp2 | NR |
| Hickman, 200951 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | not detectable | Results: unadjusted | OR: ref | NR |
| Hickson, 200852 | All-cause mortality | NR | NR |  | Results: unadjusted | NR | Sens: 70%  Spec: 69% |
| Hickson, 200852 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; NR | < 0.03 mcg/L | % Pts with event: 2% / 437 persons  Results: unadjusted | NR | Sens: 70%  Spec: 69% |
| Hickson, 200852 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; NR | > 0.03 mcg/L | % Pts with event: 12% / 207 persons  Results: unadjusted | NR | Sens: 70%  Spec: 69% |
| Hickson, 200852 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; NR | < 0.01 mcg/L | Results: adjusted | RH: ref | NR |
| Hickson, 200852 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; NR | < 0.01 mcg/L | % Pts with event: 2% / 253 persons  Results: unadjusted | N: 253  RH: ref | NR |
| Hickson, 200852 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; NR | >=0.01 mcg/L | % Pts with event: 15% / 81 persons  Results: unadjusted | N: 81  RH: 4.085  95% CI: 11.74 to 1.42  p value: 0.009; ref group: Grp1 | NR |
| Hickson, 200852 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; NR | > 0.01 mcg/L< 0.03 mcg/L | % Pts with event: 3% / 184 persons  Results: unadjusted | N: 184  p value: NS;  ref group: Grp1 | NR |
| Hickson, 200852 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; NR | > 0.04 mcg/L< 0.09 mcg/L | % Pts with event: 10% / 126 persons  Results: unadjusted | N: 126  RH: 3.011  95% CI: 8.61 to 1.05  p value: 0.04; ref group: Grp1 | NR |
| Hickson, 200852 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; NR | cTnT were analyzed as after grouping values at four levels: <0.01, 0.01-0.03, 0.04-0.09, >=0.01 ng/mL | Results: adjusted | RH: 1.642  95% CI: 1.07 to 2.51  p value: 0.022;  ref group: Grp1 | NR |
| Hickson, 200953 | MACE ≥ 1 year |  | Assay: cTnT  Mfg: Roche; NR | analyzed as groups: 0.01-0.03, 0.04-0.09, >=0.1 ng/mL | Results: adjusted | RH: 1.584  95% CI: 1.125 to 2.225  p value: 0.008;  ref group: Grp1 | NR |
| Hickson, 200953 | MACE ≥ 1 year |  | Assay: cTnT  Mfg: Roche; NR | < 0.01 mcg/L | Results: adjusted | RH: ref | NR |
| Hickson, 200953 | MACE ≥ 1 year |  | Assay: cTnT  Mfg: Roche; NR | analyzed as groups: 0.01-0.03, 0.04-0.09; >=0.1 ng/mL | Results: unadjusted | RH: 1.693  95% CI: 1.693 to 2.473  p value: 0.006;  ref group: Grp1 | NR |
| Hickson, 200953 | MACE ≥ 1 year | NR | Assay: cTnT  Mfg: Roche; NR | < 0.01 mcg/L | Results: unadjusted | RH: ref | NR |
| Hickson, 200953 | MACE ≥ 1 year | NR | Assay: cTnT  Mfg: Roche; NR | >=0.1 mcg/L | Results: unadjusted | N: 64  RH: 6.126  95% CI: 2.124 to 17.665  p value: 0.001;  ref group: Grp1 | NR |
| Hickson, 200953 | MACE ≥ 1 year | NR | Assay: cTnT  Mfg: Roche; NR | > 0.04 mcg/L< 0.1 mcg/L | Results: unadjusted | N: 115  RH: 4.478  95% CI: 1.656 to 12.109  p value: 0.003;  ref group: Grp1 | NR |
| Hickson, 200953 | MACE ≥ 1 year | NR | Assay: cTnT  Mfg: Roche; NR | > 0.01 mcg/L< 0.03 mcg/L | Results: unadjusted | N: 160  RH: 2.52  95% CI: 0.897 to 7.079  p value: 0.08;  ref group: Grp1 | NR |
| Hickson, 200953 | MACE ≥ 1 year | NR | Assay: cTnT  Mfg: Roche; NR | < 0.01 mcg/L | Results: unadjusted | N: 264  RH: ref | NR |
| Hocher, 200354 | All-cause mortality | Days: 775 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.054 mcg/L | NR | N: 84  RR: 1  ; ref group: other; ref group: all diabetic Pts | NR |
| Hocher, 200354 | All-cause mortality | Days: 775 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.054 mcg/L | NR | N: 43  RR: 1.464  95% CI: 0.667 to 3.216  p value: 0.342; ref group: Grp1 | NR |
| Hocher, 200354 | All-cause mortality | Days: 775 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.054 mcg/L | NR | N: 161  RR: 1;  ref group: other;  ref group: all non-diabetic Pts | NR |
| Hocher, 200354 | All-cause mortality | Days: 775 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.054 mcg/L | NR | N: 30  RR: 3.998  95% CI: 1.583 to 10.098  p value: 0.003;  ref group: Grp1 | NR |
| Hocher, 200354 | All-cause mortality | Days: 775 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.054 mcg/L | NR | N: 245  RR: 1;  ref group: other;  ref group: total sample | NR |
| Hocher, 200354 | All-cause mortality | Days: 775 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.054 mcg/L | NR | N: 73  RR: 2.75  95% CI: 1.538 to 4.916  p value: 0.001;  ref group: Grp1 | NR |
| Hocher, 200354 | Cardio mortality | Days: 775 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.054 mcg/L | NR | N: 84  RR: 1 | NR |
| Hocher, 200354 | Cardio mortality | Days: 775 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.054 mcg/L | NR | N: 28  RR: 1.195  95% CI: 0.45 to 3.173  p value: 0.72;  ref group: Grp1 | NR |
| Hocher, 200354 | Cardio mortality | Days: 775 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.054 mcg/L | NR | N: 161  RR: 1;  ref group: other;  ref group: all non-diabetic Pts | NR |
| Hocher, 200354 | Cardio mortality | Days: 775 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.054 mcg/L | NR | N: 13  RR: 5.378  95% CI: 1.108 to 26.1  p value: 0.037;  ref group: Grp1 | NR |
| Hocher, 200354 | Cardio mortality | Days: 775 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.054 mcg/L | NR | N: 245  RR: 1;  ref group: other;  ref group: total sample | NR |
| Hocher, 200354 | Cardio mortality | Days: 775 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.054 mcg/L | NR | N: 41  RR: 2.478  95% CI: 1.129 to 5.436  p value: 0.024;  ref group: Grp1 | NR |
| Hocher, 200455 | All-cause mortality | Days: 1140 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.039 mcg/L | Results: unadjusted | RR: 1 | NR |
| Hocher, 200455 | All-cause mortality | Days: 1140 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.039 mcg/L | Results: unadjusted | RR: 9.06  95% CI: 2.62 to 31.35  p value: 0.001;  ref group: Grp1 | NR |
| Hocher, 200455 | All-cause mortality | Days: 1140 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.039 mcg/L | Results: unadjusted | RR: 1 | NR |
| Hocher, 200455 | All-cause mortality | Days: 1140 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.039 mcg/L | Results: unadjusted | RR: 3.22  95% CI: 1.6 to 6.49  p value: 0.001;  ref group: Grp1 | NR |
| Hocher, 200455 | Cardio mortality | Days: 1140 | NR | NR | Results: unadjusted | RR: 17.17  95% CI: 2.13 to 138.29  p value: 0.008;  ref group: Grp1 | NR |
| Hocher, 200455 | Cardio mortality | Days: 1140 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.039 mcg/L | Results: unadjusted | N: 123  RR: 1;  ref group: other;  ref group: total sample | NR |
| Hocher, 200455 | Cardio mortality | Days: 1140 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.039 mcg/L | Results: unadjusted | RR: 1;  ref group: Grp1 | NR |
| Hocher, 200455 | Cardio mortality | Days: 1140 | NR | NR | NR | RR: 4.2  95% CI: 1.6 to 11.07  p value: 0.004;  ref group: Grp1 | NR |
| Hocher, 200455 | Cardio mortality | Days: 1140 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.039 mcg/L | NR | N: 122  ref group: other;  ref group: total sample | NR |
| Hocher, 200455 | Cardio mortality | Days: 1140 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.039 mcg/L | NR | RR: 1  ref group: Grp1 | NR |
| Hocher, 200856 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | < 0.053 mcg/L | Results: adjusted | RR: 1  p value: 0.048 | NR |
| Hocher, 200856 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.053 mcg/L | Results: adjusted | RR: 2.01  95% CI: 1.01 to 4.01  p value: 0.048;  ref group: Grp1 | NR |
| Hocher, 200856 | All-cause mortality | Weeks: 52 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.034 mcg/L | Results: adjusted | RR: 1  p value: <0.001 | NR |
| Hocher, 200856 | All-cause mortality | Weeks: 52 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.034 mcg/L | Results: adjusted | RR: 3.54  95% CI: 1.92 to 6.54  p value: <0.001;  ref group: Grp1 | NR |
| Hocher, 200856 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | < 0.039 mcg/L | Results: adjusted | RR: 1  p value: <0.001 | NR |
| Hocher, 200856 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.039 mcg/L | Results: adjusted | RR: 2.66  95% CI: 1.69 to 4.18  p value: <0.001;  ref group: Grp1 | NR |
| Hocher, 200856 | Cardio mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | < 0.053 mcg/L | Results: adjusted | RR: 1  p value: 0.23 | NR |
| Hocher, 200856 | Cardio mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.053 mcg/L | Results: adjusted | RR: 1.69  95% CI: 0.72 to 3.96  p value: 0.23;  ref group: Grp1 | NR |
| Hocher, 200856 | Cardio mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | < 0.034 mcg/L | Results: adjusted | RR: 1  p value: 0.004 | NR |
| Hocher, 200856 | Cardio mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.034 mcg/L | Results: adjusted | RR: 5.16  95% CI: 1.67 to 15.88  p value: 0.004;  ref group: Grp1 | NR |
| Hocher, 200856 | Cardio mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | < 0.039 mcg/L | Results: adjusted | RR: 1  p value: 0.001 | NR |
| Hocher, 200856 | Cardio mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.039 mcg/L | Results: adjusted | RR: 2.99  95% CI: 1.53 to 5.86  p value: 0.001;  ref group: Grp1 | NR |
| Hojs, 200557 | Cardio mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | < 0.05 mcg/L | Pts with event: 3 / 51 persons  Results: unadjusted | NR | NR |
| Hojs, 200557 | Cardio mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | < 0.1 mcg/L | Pts with event: 5 / 66 persons  Results: unadjusted | NR | NR |
| Hojs, 200557 | Cardio mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.05 mcg/L | Pts with event: 11 / 39 persons  Results: unadjusted | NR | NR |
| Hojs, 200557 | Cardio mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | Pts with event: 9 / 24 persons  Results: unadjusted | NR | NR |
| Holden, 201258 | All-cause mortality | Years: 3.5 | Assay: cTnT  Mfg: Roche; E170 Analyzer - immunoassay |  | Results: adjusted | RH: 0.76  95% CI: 0.24 to 2.4  p value: 0.2;  ref group: Grp1 | NR |
| Holden, 201258 | All-cause mortality | Years: 3.5 | Assay: cTnT  Mfg: Roche; E170 Analyzer - immunoassay |  | Results: adjusted | RH: 1 | NR |
| Hung, 200459 | MACE < 1 year | NR | Assay: cTnI  Mfg: DPC; immulite | < 0.2 ng/L | Results: adjusted | OR: 1  p value: 0.012 | NR |
| Hung, 200459 | MACE < 1 year | NR | Assay: cTnI  Mfg: DPC; immulite | > 0.2 ng/L | Results: adjusted | OR: 15  95% CI: 1.8 to 125.5  p value: 0.012;  ref group: Grp1 | NR |
| Hung, 200459 | MACE < 1 year | NR | Assay: cTnI  Mfg: DPC; immulite | < 0.2 ng/L | Results: unadjusted | OR: 1  p value: 0.019 | NR |
| Hung, 200459 | MACE < 1 year | NR | Assay: cTnI  Mfg: DPC; immulite | > 0.2 ng/L | Results: unadjusted | OR: 8  95% CI: 1.4 to 45.5  p value: 0.019;  ref group: Grp1 | NR |
| Hussein, 200460 | All-cause mortality | NR | Assay: cTnI  Mfg: other  Mfg: Abbott; NR | < 0 ng/L | Pts with event: 8 / 84 persons  Results: unadjusted | NR | NR |
| Hussein, 200460 | All-cause mortality | NR | Assay: cTnI  Mfg: other  Mfg: Abbott; NR | > 0 ng/L | Pts with event: 4 / 9 persons  Results: unadjusted | NR | NR |
| Ie, 200461 | All-cause mortality | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.03 ng/L | Pts with event: 0  % Pts with event: 0% / 9 persons | NR | NR |
| Ie, 200461 | All-cause mortality | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.03 mcg/L | Pts with event: 16 / 40 persons | NR | NR |
| Ie, 200461 | MACE ≥ 1 year | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.03 mcg/L | Pts with event: 5  No. of events: 7 / 30 persons | NR | NR |
| Ie, 200461 | MACE ≥ 1 year | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.03 ng/L | Pts with event: 0  No. of events: 0 / 19 persons | NR | NR |
| Iliou, 200363 | All-cause mortality | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.1 mcg/L | Pts with event: 41  % Pts with event: 20.6% / 199 persons  Results: adjusted | N: 199  RR: 1 | NR |
| Iliou, 200363 | All-cause mortality | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.15 mcg/L | Pts with event: 49  % Pts with event: 24.5% / 200 persons  Results: adjusted | NR | NR |
| Iliou, 200363 | All-cause mortality | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | Pts with event: 23  % Pts with event: 23.4% / 47 persons  Results: adjusted | N: 47  RR: 1.83  95% CI: 1.1 to 3.1  p value: 0.03;  ref group: Grp1 | NR |
| Iliou, 200363 | All-cause mortality | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.15 mcg/L | Pts with event: 15  % Pts with event: 32.6% / 46 persons  Results: adjusted | NR | NR |
| Iliou, 200363 | Cardio mortality | Years: 1 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.1 mcg/L | Pts with event: 8  % Pts with event: 3.8% / 210 persons  Results: adjusted | N: 199  RR: 1 | NR |
| Iliou, 200363 | Cardio mortality | Years: 1 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.15 mcg/L | Pts with event: 15  % Pts with event: 7.1% / 212 persons  Results: adjusted | NR | NR |
| Iliou, 200363 | Cardio mortality | Years: 1 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | Pts with event: 9  % Pts with event: 18.7% / 48 persons  Results: adjusted | N: 47  RR: 2.9  95% CI: 1.05 to 7.9  p value: 0.04;  ref group: Grp1 | NR |
| Iliou, 200363 | Cardio mortality | Years: 1 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.15 mcg/L | Pts with event: 2  % Pts with event: 4.3% / 46 persons  Results: adjusted | NR | NR |
| Iliou, 200363 | MACE ≥ 1 year | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.1 mcg/L | Pts with event: 34  % Pts with event: 17.1% / 199 persons  Results: adjusted | N: 199  RR: 1 | NR |
| Iliou, 200363 | MACE ≥ 1 year | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.15 mcg/L | Pts with event: 42  % Pts with event: 21% / 200 persons  Results: adjusted | NR | NR |
| Iliou, 200363 | MACE ≥ 1 year | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | Pts with event: 15  % Pts with event: 31.9% / 47 persons  Results: adjusted | N: 47  RR: 1.9  95% CI: 1.02 to 3.4  p value: 0.04;  ref group: Grp1 | NR |
| Iliou, 200363 | MACE ≥ 1 year | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.15 mcg/L | Pts with event: 7  % Pts with event: 15.2% / 46 persons  Results: adjusted | NR | NR |
| Ilva, 200864 | All-cause mortality | NR | Assay: cTnI  Mfg: other  Mfg: Abbott; other; Architect STAT | < 0.032 mcg/L | / 67 persons  Results: unadjusted | N: 67  RR: | NR |
| Ilva, 200864 | All-cause mortality | NR | Assay: cTnI  Mfg: other  Mfg: Abbott; other; Architect STAT | > 0.032 mcg/L | / 96 persons  Results: unadjusted | N: 96 (59% - cTnI)  RR: 1.4  95% CI: 0.7 to 2.8  p value: NS;  ref group: Grp3 | NR |
| Ilva, 200864 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | < 0.03 mcg/L | / 90 persons  Results: unadjusted | N: 90  RR: NR | NR |
| Ilva, 200864 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.03 mcg/L | / 73 persons  Results: unadjusted | N: 73 (45% - cTnT)  RR: 1.3  95% CI: 0.7 to 2.5  p value: NS;  ref group: Grp1 | NR |
| Ishii, 200165 | All-cause mortality | Years: 2 | NR | NR | NR | NR | AUC: 0.517  95% CI: 0.36 to 0.674  Sens: 17.60%  Spec: 96.30% |
| Ishii, 200165 | All-cause mortality | Years: 2 | NR | NR | NR | NR | AUC: 0.517  95% CI: 0.36 to 0.674  Sens: 17.60%  Spec: 96.30% |
| Ishii, 200165 | All-cause mortality | Years: 2 | Assay: cTnI  Mfg: Beckman; access | < 0.1 mcg/L | Pts with event: 16  % Pts with event: 17% / 94 persons | NR | AUC: 0.517  95% CI: 0.36 to 0.674  Sens: 17.60%  Spec: 96.30% |
| Ishii, 200165 | All-cause mortality | Years: 2 | Assay: cTnI  Mfg: Beckman; access | > 0.1 mcg/L | Pts with event: 3  % Pts with event: 50% / 6 persons | NR | AUC: 0.517  95% CI: 0.36 to 0.674  Sens: 17.60%  Spec: 96.30% |
| Ishii, 200165 | All-cause mortality | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.1 mcg/L | Pts with event: 7  % Pts with event: 9% / 75 persons  Results: adjusted | N: 75  RH: ref | AUC: 0.857  95% CI: 0.773 to 0.941  Sens: 62.30%  Spec: 86.70% |
| Ishii, 200165 | All-cause mortality | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | Pts with event: 12  % Pts with event: 48% / 25 persons  Results: adjusted | N: 25  RH: 3.71  95% CI: 2.66 to 4.77  p value: <0.05;  ref group: Grp1 | AUC: 0.857  95% CI: 0.773 to 0.941  Sens: 62.30%  Spec: 86.70% |
| Ishii, 200165 | Cardio mortality | Years: 2 | NR | NR | Results: adjusted | NR | AUC: 0.861  95% CI: 0.749 to 0.972  Sens: 69.50%  Spec: 82.50% |
| Ishii, 200165 | Cardio mortality | Years: 2 | Assay: Access | NR | Results: adjusted | NR | AUC: 0.861  95% CI: 0.749 to 0.972  Sens: 69.50%  Spec: 82.50% |
| Ishii, 200165 | Cardio mortality | Years: 2 | Assay: cTnT  Mfg: Roche; other; ECLusys | < 0.1 mcg/L | Pts with event: 3  % Pts with event: 4% / 75 persons  Results: adjusted | N: 75  RH: ref | AUC: 0.861  95% CI: 0.749 to 0.972  Sens: 69.50%  Spec: 82.50% |
| Ishii, 200165 | Cardio mortality | Years: 2 | Assay: cTnT  Mfg: Roche; other; ECLusys | > 0.1 mcg/L | Pts with event: 7  % Pts with event: 28% / 25 persons  Results: adjusted | N: 25  RH: 6.24  95% CI: 4.89 to 7.59  p value: <0.001;  ref group: Grp1 | AUC: 0.861  95% CI: 0.749 to 0.972  Sens: 69.50%  Spec: 82.50% |
| Ishii, 200165 | Cardio mortality | Years: 2 | NR | NR | NR | NR | AUC: 0.609  95% CI: 0.394 to 0.824  Sens: 30.30%  Spec: 94.40% |
| Ishii, 200165 | Cardio mortality | Years: 2 | Assay: cTnI  Mfg: Beckman | > 0.1 mcg/L | Pts with event: 3  % Pts with event: 50% / 6 persons | NR | AUC: 0.609  95% CI: 0.394 to 0.824  Sens: 30.30%  Spec: 94.40% |
| Ishii, 200165 | Cardio mortality | Years: 2 | Assay: cTnI  Mfg: Beckman; access | < 0.1 mcg/L | Pts with event: 7  % Pts with event: 7% / 94 persons | NR | AUC: 0.609  95% CI: 0.394 to 0.824  Sens: 30.30%  Spec: 94.40% |
| Jensen, 201266 | All-cause mortality | Years: 4.4 | Assay: cTnT  Mfg: Roche; Elecsys | < or = to 14 ng/L | NR | N: 128  RH: 1 | NR |
| Jensen, 201266 | All-cause mortality | Years: 4.4 | Assay: cTnT  Mfg: Roche; Elecsys | > 14 ng/L | NR | N: 65  RH: 1.32  95% CI: 0.62 to 2.81  p value: 0.48;  ref group: Grp1 | NR |
| Jensen, 201266 | Cardio mortality | Years: 4.4 | Assay: cTnT  Mfg: Roche; Elecsys | > 14 ng/L | NR | N: 65  RH: 1.34  95% CI: 0.44 to 4.1  p value: 0.61;  ref group: Grp1 | NR |
| Kalaji, 201267 | All-cause mortality | Days: 551 | NR | NR | Results: adjusted | NR | NR |
| Kalaji, 201267 | All-cause mortality | Days: 551 | Assay: cTnT  Mfg: Roche; Elecsys | NR | Results: adjusted | NR | NR |
| Kalaji, 201267 | All-cause mortality | Days: 551 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.1 ng/L | No. of events: 27 / 115 persons  Results: adjusted | N: 115 | NR |
| Kalaji, 201267 | All-cause mortality | Days: 551 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 ng/L | No. of events: 13 / 30 persons  Results: adjusted | N: 30  RH: 1.9  95% CI: 0.9 to 3.9  p value: 0.07;  ref group: Grp1 | NR |
| Kalaji, 201267 | All-cause mortality | Days: 551 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.01 mcg/L | % Pts with event: 7.1%  No. of events: 1 / 14 persons  Results: adjusted | N: 14  RH: 1 | NR |
| Kalaji, 201267 | All-cause mortality | Days: 551 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.03 mcg/L | % Pts with event: 15.4%  No. of events: 6 / 39 persons  Results: adjusted | N: 39  RH: 1 | NR |
| Kalaji, 201267 | All-cause mortality | Days: 551 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.01 mcg/L | % Pts with event: 29.8%  No. of events: 39 / 131 persons  Results: adjusted | N: 131  RH: 3.9  95% CI: 0.5 to 28.6  p value: NS;  ref group: Grp1 | NR |
| Kalaji, 201267 | All-cause mortality | Days: 551 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.03 mcg/L | % Pts with event: 32.1%  No. of events: 34 / 106 persons  Results: adjusted | N: 106  RH: 1.9  95% CI: 0.8 to 4.7  p value: NS;  ref group: Grp1 | NR |
| Kalaji, 201267 | All-cause mortality | Days: 551 | Assay: cTnI  Mfg: other  Mfg: Siemens; other; Immulite Troponin I kit | <0.2 ng/mL | % Pts with event: 25.5%  No. of events: 24 / 94 persons  Results: adjusted | N: 94  RH: 1 | NR |
| Kalaji, 201267 | All-cause mortality | Days: 551 | Assay: cTnI  Mfg: other  Mfg: Siemens; other; Immulite Troponin I kit | >0.2 ng/mL | % Pts with event: 31.4%  No. of events: 16 / 51 persons  Results: adjusted | N: 51  RH: 1.6  95% CI: 0.8 to 3  p value: NS;  ref group: Grp1 | NR |
| Kang, 200968 | All-cause mortality | Followup NR | Assay: cTnI  Mfg: Beckman; AccuTnI | < 0.2 mcg/L | % Pts with event: 23.9% / 46 persons  Results: adjusted | N: 46  HR: 1  p value: 0.001 | NR |
| Kang, 200968 | All-cause mortality | Followup NR | Assay: cTnI  Mfg: Beckman; AccuTnI | > 0.2 mcg/L | % Pts with event: 55% / 20 persons  Results: adjusted | N: 20  HR: 5.9  95% CI: 2.06 to 16.87  p value: 0.001;  ref group: Grp1 | NR |
| Kang, 200968 | All-cause mortality | Days: 90 | Assay: cTnI  Mfg: Beckman; AccuTnI | < 0.2 mcg/L | % Pts with event: 35.2% / 71 persons  Results: adjusted | N: 71  OR: 1 | NR |
| Kang, 200968 | All-cause mortality | Days: 90 | Assay: cTnI  Mfg: Beckman; AccuTnI | > 0.2 mcg/L | % Pts with event: 60% / 50 persons  Results: adjusted | N: 50  OR: 5.13  95% CI: 1.73 to 15.18  p value: 0.003;  ref group: Grp1 | NR |
| Kang, 200968 | Cardio mortality | Followup NR | Assay: cTnI  Mfg: Beckman; AccuTnI | < 0.2 mcg/L | Results: adjusted | N: 46  HR: 1 | NR |
| Kang, 200968 | Cardio mortality | Followup NR | Assay: cTnI  Mfg: Beckman; AccuTnI | > 0.2 mcg/L | Results: adjusted | N: 20  hazard ratio: 5.17  95% CI: 1.16 to 23.16  p value: 0.032;  ref group: Grp1 | NR |
| Kanwar, 200669 | All-cause mortality | NR | Assay: cTnI  Mfg: Beckman; NR | < 0.01 mcg/L | Pts with event: 4 / 23 persons | NR | NR |
| Kanwar, 200669 | All-cause mortality | NR | Assay: cTnI  Mfg: Beckman; NR | > 0.01 mcg/L | Pts with event: 9 / 35 persons | NR | NR |
| Kanwar, 200669 | All-cause mortality | NR | Assay: cTnI  Mfg: Beckman; NR | < 0.01 mcg/L | Pts with event: 7 / 34 persons | NR | NR |
| Kanwar, 200669 | All-cause mortality | NR | Assay: cTnI  Mfg: Beckman; NR | > 0.01 mcg/L | Pts with event: 46 / 81 persons | NR | NR |
| Katerinis, 200870 | All-cause mortality | NR | Assay: cTnI  Mfg: Beckman; AccuTnI | < 0.09 mcg/L | Pts with event: 0 / 46 persons  Results: unadjusted | NR | NR |
| Katerinis, 200870 | All-cause mortality | NR | Assay: cTnI  Mfg: Beckman; AccuTnI | > 0.09 mcg/L | Pts with event: 1 / 4 persons  Results: unadjusted | NR | NR |
| Katerinis, 200870 | MACE ≥ 1 year | NR | Assay: cTnI  Mfg: Beckman; AccuTnI | < 0.09 mcg/L | Pts with event: 0 / 46 persons | NR | NR |
| Katerinis, 200870 | MACE ≥ 1 year | NR | Assay: cTnI  Mfg: Beckman; AccuTnI | > 0.09 mcg/L | Pts with event: 0 / 4 persons | NR | NR |
| Kertai, 200471 | All-cause mortality | Years: 4 | Assay: cTnT  Mfg: Roche; other; Trop T | < 0.1 ng/L | Pts with event: 9 / 42 persons  Results: unadjusted | RH: 1 | NR |
| Kertai, 200471 | All-cause mortality | Years: 4 | Assay: cTnT  Mfg: Roche; other; Trop T | > 0.1 ng/L | Pts with event: 4 / 16 persons  Results: unadjusted | RH: 0.9  95% CI: 0.3 to 3.3;  ref group: Grp1 | NR |
| Khan, 200172 | All-cause mortality | Years: 2 | Assay: cTnI  Mfg: Sanofi; access | < 0.03 mcg/L | Pts with event: 20 / 102 persons  Results: unadjusted | NR | NR |
| Khan, 200172 | All-cause mortality | Years: 2 | Assay: cTnI  Mfg: Sanofi; access | > 0.03 mcg/L | Pts with event: 4 / 24 persons  Results: unadjusted | NR | NR |
| Khan, 200172 | Cardio mortality | Years: 2 | Assay: cTnI  Mfg: Sanofi; access | < 0.03 mcg/L | Pts with event: 4 / 102 persons | NR | NR |
| Khan, 200172 | Cardio mortality | Years: 2 | Assay: cTnI  Mfg: Sanofi; access | > 0.03 mcg/L | Pts with event: 1 / 24 persons | NR | NR |
| Khan, 200172 | Hospital readmission | Years: 2 | Assay: cTnI  Mfg: Sanofi; access | < 0.03 mcg/L | No. of events: 177 / 102 persons | NR | NR |
| Khan, 200172 | Hospital readmission | Years: 2 | Assay: cTnI  Mfg: Sanofi; access | > 0.03 mcg/L | No. of events: 30 / 24 persons | NR | NR |
| Khan, 200172 | Hospital readmission | Years: 2 | Assay: cTnI  Mfg: Sanofi; access | < 0.03 mcg/L | No. of events: 53 / 102 persons | NR | NR |
| Khan, 200172 | Hospital readmission | Years: 2 | Assay: cTnI  Mfg: Sanofi; access | > 0.03 mcg/L | No. of events: 8 / 24 persons | NR | NR |
| Kontos, 200573 | All-cause mortality | Years: 1 | Assay: cTnI  Mfg: other  Mfg: from 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; from 1996-1998, used Behring Opus Magnum Analyzer. from 1998-2000, used Bayer Immuno One | For Opus assay: <=1.0 ng/mL | % Pts with event: 14% | NR | NR |
| Kontos, 200573 | All-cause mortality | Years: 1 | Assay: cTnI  Mfg: other  Mfg: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One | For Opus assay: >=2.5 ng/mL. For Bayer assay: >=0.9 ng/mL | % Pts with event: 18% | RR: 1.4  95% CI: 2.4 to 0.8;  ref group: Grp2 | NR |
| Kontos, 200573 | All-cause mortality | Years: 1 | Assay: cTnI  Mfg: other  Mfg: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One | For Opus assay: 1.0 ng/mL - 2.5 ng/mL. For Bayer assay: 0.3 ng/mL - 0.9 ng/mL | % Pts with event: 29% | RR: 2.6  95% CI: 5.2 to 1.2;  ref group: Grp2 | NR |
| Kontos, 200573 | All-cause mortality | Years: 1 | Assay: cTnI  Mfg: other  Mfg: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One | For Opus assay: <=1.0 ng/mL | % Pts with event: 4.9% | NR | NR |
| Kontos, 200573 | All-cause mortality | Years: 1 | Assay: cTnI  Mfg: other  Mfg: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One | For Opus assay: >=2.5 ng/mL. For Bayer assay: >=0.9 ng/mL | % Pts with event: 9.7% | RR: 2.1  95% CI: 3.3 to 1.3;  ref group: Grp2 | NR |
| Kontos, 200573 | All-cause mortality | Years: 1 | Assay: cTnI  Mfg: other  Mfg: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One | For Opus assay: 1.0 ng/mL - 2.5 ng/mL. For Bayer assay: 0.3 ng/mL - 0.9 ng/mL | % Pts with event: 7.1% | RR: 1.5  95% CI: 3.1 to 0.7;  ref group: Grp2 | NR |
| Kontos, 200573 | All-cause mortality | Years: 1 | Assay: cTnI  Mfg: other  Mfg: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One | For Opus assay: <=1.0 ng/mL | % Pts with event: 26% | NR | NR |
| Kontos, 200573 | All-cause mortality | Years: 1 | Assay: cTnI  Mfg: other  Mfg: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One | For Opus assay: >=2.5 ng/mL. For Bayer assay: >=0.9 ng/mL | % Pts with event: 57% | RR: 3.8  95% CI: 6.8 to 2; ref group: Grp2 | NR |
| Kontos, 200573 | All-cause mortality | Years: 1 | Assay: cTnI  Mfg: other  Mfg: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One | For Opus assay: 1.0 ng/mL - 2.5 ng/mL. For Bayer assay: 0.3 ng/mL - 0.9 ng/mL | % Pts with event: 43% | RR: 2.1  95% CI: 4.8 to 0.9;  ref group: Grp2 | NR |
| Kontos, 200573 | Cardio mortality | Years: 1 | Assay: cTnI  Mfg: other  Mfg: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One | For Opus assay: <=1.0 ng/mL | % Pts with event: 7.7% | NR | NR |
| Kontos, 200573 | Cardio mortality | Years: 1 | Assay: cTnI  Mfg: other  Mfg: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One | For Opus assay: 1.0 ng/mL - 2.5 ng/mL. For Bayer assay: 0.3 ng/mL - 0.9 ng/mL | % Pts with event: 17% | RR: 2.5  95% CI: 5.9 to 1;  ref group: Grp2 | NR |
| Kontos, 200573 | Cardio mortality | Years: 1 | Mfg: other  Mfg: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One | For Opus assay: >=2.5 ng/mL. For Bayer assay: >=0.9 ng/mL | % Pts with event: 15% | RR: 2.1  95% CI: 4 to 1.1;  ref group: Grp2 | NR |
| Kontos, 200573 | Cardio mortality | Years: 1 | Assay: cTnI  Mfg: other  Mfg: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One | For Opus assay: 1.0 ng/mL - 2.5 ng/mL. For Bayer assay: 0.3 ng/mL - 0.9 ng/mL | % Pts with event: 5.4% | RR: 2.7  95% CI: 6.5 to 1.1;  ref group: Grp2 | NR |
| Kontos, 200573 | Cardio mortality | Years: 1 | Assay: cTnI  Mfg: other  Mfg: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One | For Opus assay: >=2.5 ng/mL. For Bayer assay: >=0.9 ng/mL | % Pts with event: 7.2% | RR: 3.7  95% CI: 6.6 to 2;  ref group: Grp2 | NR |
| Kontos, 200573 | Cardio mortality | Years: 1 | Assay: cTnI  Mfg: other  Mfg: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One | For Opus assay: <=1.0 ng/mL | % Pts with event: 2% | NR | NR |
| Kontos, 200573 | Cardio mortality | Years: 1 | Assay: cTnI  Mfg: other  Mfg: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One | For Opus assay: <=1.0 ng/mL | % Pts with event: 12% | NR | NR |
| Kontos, 200573 | Cardio mortality | Years: 1 | Assay: cTnI  Mfg: other  Mfg: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One | For Opus assay: >=2.5 ng/mL. For Bayer assay: >=0.9 ng/mL | % Pts with event: 40% | RR: 4.8  95% CI: 9.3 to 2.3;  ref group: Grp2 | NR |
| Kontos, 200573 | Cardio mortality | Years: 1 | Assay: cTnI  Mfg: other  Mfg: From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One; other; From 1996-1998, used Behring Opus Magnum Analyzer. From 1998-2000, used Bayer Immuno One | For Opus assay: 1.0 ng/mL - 2.5 ng/mL. For Bayer assay: 0.3 ng/mL - 0.9 ng/mL | % Pts with event: 18% | RR: 1.6  95% CI: 4.5 to 0.5; ref group: Grp2 | NR |
| Kontos, 200574 | All-cause mortality | Years: 1 | Assay: cTnI | Negative: optimal diagnostic values, similar to those recommended by a consensus panel | % Pts with event: 3.6% / 1635 persons  Results: unadjusted | NR | NR |
| Kontos, 200574 | All-cause mortality | Years: 1 | Assay: cTnI | Positive: optimal diagnostic values, similar to those recommended by a consensus panel | % Pts with event: 5.9% / 270 persons  Results: unadjusted | NR | NR |
| Kontos, 200574 | All-cause mortality | Years: 1 | Assay: cTnI | Negative: optimal diagnostic values, similar to those recommended by a consensus panel | % Pts with event: 17% / 52 persons  Results: unadjusted | NR | NR |
| Kontos, 200574 | All-cause mortality | Years: 1 | Assay: cTnI | Positive: optimal diagnostic values, similar to those recommended by a consensus panel | % Pts with event: 47% / 34 persons  Results: unadjusted | NR | NR |
| Kontos, 200574 | All-cause mortality | Years: 1 | Assay: cTnI | Negative: optimal diagnostic values, similar to those recommended by a consensus panel | Pts with event: 19 / 95 persons  Results: unadjusted | NR | NR |
| Kontos, 200574 | All-cause mortality | Years: 1 | Assay: cTnI | Positive: optimal diagnostic values, similar to those recommended by a consensus panel | Pts with event: 28 / 39 persons  Results: unadjusted | NR | NR |
| Kontos, 200574 | All-cause mortality | Years: 1 | Assay: cTnI | Negative: optimal diagnostic values, similar to those recommended by a consensus panel | % Pts with event: 17% / 120 persons  Results: unadjusted | NR | NR |
| Kontos, 200574 | All-cause mortality | Years: 1 | Assay: cTnI | Positive: optimal diagnostic values, similar to those recommended by a consensus panel | % Pts with event: 24% / 45 persons  Results: unadjusted | NR | NR |
| Kontos, 200574 | All-cause mortality | Years: 1 | Assay: cTnI | Negative: optimal diagnostic values, similar to those recommended by a consensus panel | % Pts with event: 6.6% / 228 persons  Results: unadjusted | NR | NR |
| Kontos, 200574 | All-cause mortality | Years: 1 | Assay: cTnI | Positive: optimal diagnostic values, similar to those recommended by a consensus panel | % Pts with event: 15% / 55 persons  Results: unadjusted | NR | NR |
| Kontos, 200574 | All-cause mortality | Years: 1 | Assay: cTnI | Negative: optimal diagnostic values, similar to those recommended by a consensus panel | % Pts with event: 5.4% / 297 persons  Results: unadjusted | NR | NR |
| Kontos, 200574 | All-cause mortality | Years: 1 | Assay: cTnI | Positive: optimal diagnostic values, similar to those recommended by a consensus panel | % Pts with event: 19% / 57 persons  Results: unadjusted | NR | NR |
| Kontos, 200574 | All-cause mortality | Years: 1 | Assay: cTnI | Negative: optimal diagnostic values, similar to those recommended by a consensus panel | % Pts with event: 25% / 101 persons  Results: unadjusted | NR | NR |
| Kontos, 200574 | All-cause mortality | Years: 1 | Assay: cTnI | Positive: optimal diagnostic values, similar to those recommended by a consensus panel | % Pts with event: 53% / 45 persons  Results: unadjusted | NR | NR |
| Kontos, 200875 | All-cause mortality | Days: 30 | Assay: cTnI | Negative | % Pts with event: 3.8%  Results: unadjusted | NR | NR |
| Kontos, 200875 | All-cause mortality | Days: 30 | Assay: cTnI | Positive | % Pts with event: 10%  Results: unadjusted | NR | NR |
| Kontos, 200875 | All-cause mortality | Years: 1 | Assay: cTnI | Negative | % Pts with event: 15%  Results: unadjusted | NR | NR |
| Kontos, 200875 | All-cause mortality | Years: 1 | Assay: cTnI | Positive | % Pts with event: 26%  Results: unadjusted | NR | NR |
| Kontos, 200875 | All-cause mortality | Days: 30 | Assay: cTnI | Negative | % Pts with event: 8.6%  Results: unadjusted | NR | NR |
| Kontos, 200875 | All-cause mortality | Days: 30 | Assay: cTnI | Positive | % Pts with event: 26%  Results: unadjusted | NR | NR |
| Kontos, 200875 | All-cause mortality | Years: 1 | Assay: cTnI | Negative | % Pts with event: 32%  Results: unadjusted | NR | NR |
| Kontos, 200875 | All-cause mortality | Years: 1 | Assay: cTnI | Positive | % Pts with event: 53%  Results: unadjusted | NR | NR |
| Kontos, 200875 | All-cause mortality | Days: 30 | Assay: cTnI | Negative | % Pts with event: 0.8%  Results: unadjusted | NR | NR |
| Kontos, 200875 | All-cause mortality | Days: 30 | Assay: cTnI | Positive | % Pts with event: 3.9%  Results: unadjusted | NR | NR |
| Kontos, 200875 | All-cause mortality | Years: 1 | Assay: cTnI | Negative | % Pts with event: 5.1%  Results: unadjusted | NR | NR |
| Kontos, 200875 | All-cause mortality | Years: 1 | Assay: cTnI | Positive | % Pts with event: 9.9%  Results: unadjusted | NR | NR |
| Kontos, 200875 | All-cause mortality | Days: 30 | Assay: cTnI | Negative | % Pts with event: 3.3%  Results: unadjusted | NR | NR |
| Kontos, 200875 | All-cause mortality | Days: 30 | Assay: cTnI | Positive | % Pts with event: 10%  Results: unadjusted | NR | NR |
| Kontos, 200875 | All-cause mortality | Days: 30 | Assay: cTnI | Negative | % Pts with event: 9.6%  Results: unadjusted | NR | NR |
| Kontos, 200875 | All-cause mortality | Years: 1 | Assay: cTnI | Negative | % Pts with event: 30%  Results: unadjusted | NR | NR |
| Kontos, 200875 | All-cause mortality | Years: 1 | Assay: cTnI | Positive | % Pts with event: 54%  Results: unadjusted | NR | NR |
| Kontos, 200875 | All-cause mortality | Days: 30 | Assay: cTnI | Negative | % Pts with event: 1%  Results: unadjusted | NR | NR |
| Kontos, 200875 | All-cause mortality | Days: 30 | Assay: cTnI | Positive | % Pts with event: 4.7%  Results: unadjusted | NR | NR |
| Kostrubiec, 201076 | All-cause mortality | Days: 30 | NR | GFR < 35 and Troponin positive | Pts with event: 10 / 21 persons | NR | NR |
| Lamb, 200777 | All-cause mortality | NR | NR | NR | Results: adjusted | NR | Sens: 31  95% CI: 17 to 48  Spec: 85  95% CI: 79 to 90 |
| Lamb, 200777 | All-cause mortality | NR | NR | NR | Results: adjusted | NR | Sens: 51  95% CI: 35 to 68  Spec: 80  95% CI: 73 to 85 |
| Lamb, 200777 | All-cause mortality | NR | NR | NR | Results: adjusted | NR | Sens: 67  95% CI: 50 to 81  Spec: 62  95% CI: 55 to 69 |
| Lamb, 200777 | All-cause mortality | NR | NR | NR | Results: adjusted | NR | AUC: 0.75  p value: <0.001  95% CI: 0.663 to 0.838  Sens: 60  95% CI: 42 to 76  Spec: 73  95% CI: 66 to 80 |
| Lamb, 200777 | All-cause mortality | NR | Assay: cTnI  Mfg: Bayer; Advair Centaur (standard) | < 0.07 mcg/L | Pts with event: 27 / 177 persons  Results: adjusted | N: 177  RH: REF | Sens: 31  95% CI: 17 to 48  Spec: 85  95% CI: 79 to 90 |
| Lamb, 200777 | All-cause mortality | NR | Assay: cTnI  Mfg: Bayer; Advair Centaur (standard) | > 0.07 mcg/L | Pts with event: 12 / 38 persons  Results: adjusted | N: 38  RH: 1.4  95% CI: 0.7 to 3  p value: 0.3;  ref group: Grp1 | Sens: 31  95% CI: 17 to 48  Spec: 85  95% CI: 79 to 90 |
| Lamb, 200777 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | < 0.01 mcg/L | Pts with event: 13 / 127 persons  Results: adjusted | N: 127  RH: REF | Sens: 67  95% CI: 50 to 81  Spec: 62  95% CI: 55 to 69 |
| Lamb, 200777 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | < 0.03 mcg/L | Pts with event: 19 / 165 persons  Results: adjusted | N: 165  RH: REF | Sens: 51  95% CI: 35 to 68  Spec: 80  95% CI: 73 to 85 |
| Lamb, 200777 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.01 mcg/L | Pts with event: 26 / 95 persons  Results: adjusted | N: 95  RH: 2  95% CI: 1 to 3.9  p value: 0.05;  ref group: Grp1 | Sens: 67  95% CI: 50 to 81  Spec: 62  95% CI: 55 to 69 |
| Lamb, 200777 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.03 mcg/L | Pts with event: 20 / 57 persons  Results: adjusted | N: 57  RH: 2.1  95% CI: 1.1 to 4  p value: 0.03;  ref group: Grp1 | Sens: 51  95% CI: 35 to 68  Spec: 80  95% CI: 73 to 85 |
| Lamb, 200777 | All-cause mortality | NR | Assay: hscTnI  Mfg: Bayer; other; Advia Centaur (Ultra) | < 0.04 mcg/L | Pts with event: 14 / 129 persons  Results: adjusted | N: 129  RH: REF | AUC: 0.75  p value: <0.001  95% CI: 0.663 to 0.838  Sens: 60  95% CI: 42 to 76  Spec: 73  95% CI: 66 to 80 |
| Lamb, 200777 | All-cause mortality | NR | Assay: hscTnI  Mfg: Bayer; other; Advia Centaur (Ultra) | > 0.04 mcg/L | Pts with event: 21 / 63 persons  Results: adjusted | N: 63  RH: 1.9  95% CI: 0.9 to 3.9  p value: 0.08;  ref group: Grp1 | AUC: 0.75  p value: <0.001  95% CI: 0.663 to 0.838  Sens: 60  95% CI: 42 to 76  Spec: 73  95% CI: 66 to 80 |
| Lang, 200178 | All-cause mortality | Years: 2 |  | NR | NR | NR | Sens: 5  Spec: 93 |
| Lang, 200178 | All-cause mortality | Years: 2 | Assay: cTnI  Mfg: Dade Behring; other; Stratus Cardiac Troponin I | < 0.4 mcg/L | Pts with event: 17 / 93 persons | NR | Sens: 5  Spec: 93 |
| Lang, 200178 | All-cause mortality | Years: 2 | Assay: cTnI  Mfg: Dade Behring; other; Stratus Cardiac Troponin I | > 0.4 mcg/L | Pts with event: 1 / 7 persons | NR | Sens: 5  Spec: 93 |
| Lang, 200178 | All-cause mortality | Years: 2 | Assay: cTnI  Mfg: other  Mfg: Astra; other; Cardiac STATus Troponin I rapid test | < 0.1 mcg/L | Pts with event: 10 / 73 persons | NR | NR |
| Lang, 200178 | All-cause mortality | Years: 2 | Assay: cTnI  Mfg: other  Mfg: Astra; other; Cardiac STATus Troponin I rapid test | > 0.1 mcg/L | Pts with event: 8 / 27 persons | NR | NR |
| Lang, 200178 | All-cause mortality | Years: 2 | Assay: cTnT  Mfg: other  Mfg: Boehringer Mannheim; other; ELISA | < 0.1 mcg/L | Pts with event: 11 / 78 persons | NR | NR |
| Lang, 200178 | All-cause mortality | Years: 2 | Assay: cTnT  Mfg: other  Mfg: Boehringer Mannheim; other; ELISA | > 0.1 mcg/L | Pts with event: 7 / 22 persons | NR | NR |
| Lang, 200178 | All-cause mortality | Years: 2 | Assay: cTnT  Mfg: other  Mfg: Boehringer Mannheim; other; TropT-sensitive rapid test | < 0.1 mcg/L | Pts with event: 6 / 59 persons | NR | NR |
| Lang, 200178 | All-cause mortality | Years: 2 | Assay: cTnT  Mfg: other  Mfg: Boehringer Mannheim; other; TropT-sensitive rapid test | > 0.1 mcg/L | Pts with event: 12 / 41 persons | NR | NR |
| Lang, 200178 | Cardio mortality | Years: 2 | Assay: cTnT  Mfg: other  Mfg: Boehringer Mannheim; other; ELISA | < 0.1 mcg/L | Pts with event: 8 / 78 persons | NR | NR |
| Lang, 200178 | Cardio mortality | Years: 2 | Assay: cTnT  Mfg: other  Mfg: Boehringer Mannheim; other; ELISA | > 0.1 mcg/L | Pts with event: 5 / 22 persons | NR | NR |
| Lang, 200178 | Cardio mortality | Years: 2 | Assay: cTnI  Mfg: Dade Behring; other; Stratus Cardiac Troponin I | < 0.4 mcg/L | Pts with event: 12 / 93 persons | NR | NR |
| Lang, 200178 | Cardio mortality | Years: 2 | Assay: cTnI  Mfg: Dade Behring; other; Stratus Cardiac Troponin I | > 0.4 mcg/L | Pts with event: 1 / 7 persons | NR | NR |
| Lang, 200178 | Cardio mortality | Years: 2 | Assay: cTnI  Mfg: other  Mfg: Astra; other; Cardiac STATus Troponin I rapid test | < 0.1 mcg/L | Pts with event: 5 / 73 persons | NR | NR |
| Lang, 200178 | Cardio mortality | Years: 2 | Assay: cTnI  Mfg: other  Mfg: Astra; other; Cardiac STATus Troponin I rapid test | > 0.1 mcg/L | Pts with event: 8 / 27 persons | NR | NR |
| Lang, 200178 | Cardio mortality | Years: 2 | Assay: cTnT  Mfg: other  Mfg: Boehringer Mannheim; other; TropT-sensitive rapid test | < 0.1 mcg/L | Pts with event: 3 / 59 persons | NR | NR |
| Lang, 200178 | Cardio mortality | Years: 2 | Assay: cTnT  Mfg: other  Mfg: Boehringer Mannheim; other; TropT-sensitive rapid test | > 0.1 mcg/L | Pts with event: 10 / 41 persons | NR | NR |
| Lang, 200178 | Subs. MI | Years: 2 | Assay: cTnT  Mfg: other  Mfg: Boehringer Mannheim; other; TropT-sensitive rapid test | < 0.1 mcg/L | Pts with event: 4 / 59 persons | NR | NR |
| Lang, 200178 | Subs. MI | Years: 2 | Assay: cTnT  Mfg: other  Mfg: Boehringer Mannheim; other; TropT-sensitive rapid test | > 0.1 mcg/L | Pts with event: 10 / 41 persons | NR | NR |
| Lang, 200178 | Subs. MI | Years: 2 | Assay: cTnI  Mfg: Dade Behring; other; Stratus Cardiac Troponin I | < 0.4 mcg/L | Pts with event: 13 / 93 persons | NR | NR |
| Lang, 200178 | Subs. MI | Years: 2 | Assay: cTnI  Mfg: Dade Behring; other; Stratus Cardiac Troponin I | > 0.4 mcg/L | Pts with event: 1 / 7 persons | NR | NR |
| Lang, 200178 | Subs. MI | Years: 2 | Assay: cTnI  Mfg: other  Mfg: Astra; other; Cardiac STATus Troponin I rapid test | < 0.1 mcg/L | Pts with event: 5 / 73 persons | NR | NR |
| Lang, 200178 | Subs. MI | Years: 2 | Assay: cTnI  Mfg: other  Mfg: Astra; other; Cardiac STATus Troponin I rapid test | > 0.1 mcg/L | Pts with event: 9 / 27 persons | NR | NR |
| Lang, 200178 | Subs. MI | Years: 2 | Assay: cTnT  Mfg: other  Mfg: Boehringer Mannheim; other; ELISA | < 0.1 mcg/L | Pts with event: 9 / 78 persons | NR | NR |
| Lang, 200178 | Subs. MI | Years: 2 | Assay: cTnT  Mfg: other  Mfg: Boehringer Mannheim; other; ELISA | > 0.1 mcg/L | Pts with event: 5 / 22 persons | NR | NR |
| Le Goff, 200779 | All-cause mortality | Years: 3 |  |  | % Pts with event: 73.2% / 22 persons  Results: adjusted | NR | NR |
| Le Goff, 200779 | All-cause mortality | Years: 3 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.03 mcg/L | Pts with event: 61 / 86 persons  Results: adjusted | NR | NR |
| Le Goff, 200779 | All-cause mortality | Years: 3 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.031 mcg/L< 0.1 mcg/L | % Pts with event: 43% / 7 persons  Results: adjusted | NR | NR |
| Le Goff, 200779 | All-cause mortality | Years: 3 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | % Pts with event: 53% / 32 persons  Results: adjusted | NR | NR |
| Le Goff, 200779 | Cardio mortality | Years: 3 | NR | NR | % Pts with event: 32% / 22 persons  Results: adjusted | NR | NR |
| Le Goff, 200779 | Cardio mortality | Years: 3 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.03 mcg/L | % Pts with event: 61% / 86 persons  Results: adjusted | NR | NR |
| Le Goff, 200779 | Cardio mortality | Years: 3 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.031 mcg/L< 0.1 mcg/L | % Pts with event: 14% / 7 persons  Results: adjusted | NR | NR |
| Le Goff, 200779 | Cardio mortality | Years: 3 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | % Pts with event: 9% / 32 persons  Results: adjusted | NR | NR |
| Lowbeer, 200280 | All-cause mortality | NR | Assay: cTnT  Mfg: other  Mfg: Boehringer; other; ELISA | < 0.04 mcg/L | Pts with event: 3 / 12 persons | N: 16 | NR |
| Lowbeer, 200280 | All-cause mortality | NR | Assay: cTnT  Mfg: other  Mfg: Boehringer; other; ELISA | > 0.04 mcg/L | Pts with event: 12 / 14 persons | N: 10  Exponent Beta: 6.54  SE: 0.54  p value: 0.00056;  ref group: Grp1 | NR |
| Lowbeer, 200280 | Cardio mortality | NR | Assay: cTnT  Mfg: other  Mfg: Boehringer; other; ELISA | < 0.04 mcg/L | Pts with event: 3 / 12 persons | NR | NR |
| Lowbeer, 200280 | Cardio mortality | NR | Assay: cTnT  Mfg: other  Mfg: Boehringer; other; ELISA | > 0.04 mcg/L | Pts with event: 8 / 14 persons | NR | NR |
| Lowbeer, 200381 | Other composite (survival) | Years: 2.7 | Assay: cTnT  Mfg: Roche; Elecsys | NR | Pts with event: NR/ 49 persons | NR | NR |
| Lowbeer, 200381 | Other composite (survival) | Years: 2.7 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.1 mcg/L | % Pts with event: 72% / 35 persons | NR | NR |
| Lowbeer, 200381 | Other composite (survival) | Years: 2.7 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | % Pts with event: 65% / 14 persons | NR | NR |
| Lowbeer, 200381 | Other composite (survival) | NR | Assay: cTnT  Mfg: Roche; Elecsys | < 0.1 mcg/L | % Pts with event: 75% / 44 persons | NR | NR |
| Lowbeer, 200381 | Other composite (survival) | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | % Pts with event: 45% / 20 persons | NR | NR |
| Lowbeer, 200381 | Other composite (survival) | Years: 2.7 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.1 mcg/L | % Pts with event: 74.4% / 81 persons  Results: adjusted | N: 81  RH: 1 | NR |
| Lowbeer, 200381 | Other composite (survival) | Years: 2.7 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | % Pts with event: 45.5% / 34 persons  Results: adjusted | N: 34  RH: 2.66  95% CI: 1.07 to 10.95  p value: <0.05;  ref group: Grp1 | NR |
| Mallamaci, 200282 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | < 0.01 mcg/L | Pts with event: 0 / 12 persons  Results: adjusted | NR | NR |
| Mallamaci, 200282 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | < 0.048 mcg/L | Results: adjusted | RH: 1  95% CI: to | NR |
| Mallamaci, 200282 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.049 mcg/L< 0.098 mcg/L | Results: adjusted | RH: 1.15  95% CI: 0.53 to 2.51  p value: 0.73;  ref group: Grp2 | NR |
| Mallamaci, 200282 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.098 mcg/L | Results: adjusted | RH: 2.39  95% CI: 1.13 to 5.06  p value: 0.02;  ref group: Grp2 | NR |
| Mallamaci, 200282 | Cardio mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | < 0.048 mcg/L | Results: adjusted | RH: 1 | NR |
| Mallamaci, 200282 | Cardio mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.049 mcg/L< 0.098 mcg/L | Results: adjusted | RH: 1.19  95% CI: 0.5 to 2.82  p value: 0.69;  ref group: Grp1 | NR |
| Mallamaci, 200282 | Cardio mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.098 mcg/L | Results: adjusted | RH: 2.35  95% CI: 1.01 to 5.49  p value: 0.048;  ref group: Grp1 | NR |
| Martin, 199883 | All-cause mortality | NR | Assay: cTnI  Mfg: Dade Behring; stratus | < 0.8 mcg/L | Pts with event: 5  % Pts with event: 15% / 33 persons  Results: unadjusted | NR | NR |
| Martin, 199883 | All-cause mortality |  | Assay: cTnI  Mfg: Dade Behring; stratus | > 0.8 mcg/L | Pts with event: 4  % Pts with event: 29% / 14 persons  Results: unadjusted | NR | NR |
| McGill, 201085 | All-cause mortality | Years: 3.9 | Assay: hscTnT  Mfg: Roche; E411 analyzer | Ln hs-cTnT, cut off 3 ng/L | Results: adjusted | N: 143  RH: 1.404  95% CI: 1.001 to 1.968  p value: 0.049 | NR |
| McMurray, 201186 | Cardio mortality | Years: 2.4 | Assay: cTnT  Mfg: Roche; 4th generation TnT assay | <0.028 ng/mL | NR | N: 230  RH: 1.42  95% CI: 1.05 to 1.93  p value: 0.0001;  ref group: Grp1 | NR |
| McMurray, 201186 | Cardio mortality | Years: 2.4 | Assay: cTnT  Mfg: Roche; 4th generation TnT assay | >0.028 ng/mL | NR | N: 217  RH: 1.5  95% CI: 2.13 to 10.6  p value: 0.0001;  ref group: Grp1 | NR |
| McMurray, 201186 | Cardio mortality | Years: 2.4 | Assay: cTnT  Mfg: Roche; 4th generation TnT assay | Undetectable | NR | N: 548  RH: 1 | NR |
| Melloni, 200887 | All-cause mortality | Followup NR | Assay: cTnI | <1 x ULN | % Pts with event: 3.3% / 5529 persons | NR | NR |
| Melloni, 200887 | All-cause mortality | Followup NR | Assay: cTnI | >3 x ULN | % Pts with event: 7.4% / 20843 persons | NR | NR |
| Melloni, 200887 | All-cause mortality | Followup NR | Assay: cTnI | 1-3 x ULN | % Pts with event: 5.4% / 5214 persons | NR | NR |
| Melloni, 200887 | All-cause mortality | Followup NR | Assay: cTnT | <1 x ULN | % Pts with event: 3.7% / 5529 persons | NR | NR |
| Melloni, 200887 | All-cause mortality | Followup NR | Assay: cTnT | >3 x ULN | % Pts with event: 7.3% / 20843 persons | NR | NR |
| Melloni, 200887 | All-cause mortality | Followup NR | Assay: cTnT | 1-3 x ULN | % Pts with event: 3.5% / 5214 persons | NR | NR |
| Melloni, 200887 | All-cause mortality | Followup NR | Assay: cTnI | <1 x ULN | % Pts with event: 1.7% / 5529 persons | NR | NR |
| Melloni, 200887 | All-cause mortality | Followup NR | Assay: cTnI | >3 x ULN | % Pts with event: 2.1% / 20843 persons | NR | NR |
| Melloni, 200887 | All-cause mortality | Followup NR | Assay: cTnI | 1-3 x ULN | % Pts with event: 2.1% / 5214 persons | NR | NR |
| Melloni, 200887 | All-cause mortality | Followup NR | Assay: cTnT | <1 x ULN | % Pts with event: 1% / 5529 persons | NR | NR |
| Melloni, 200887 | All-cause mortality | Followup NR | Assay: cTnT | > 3 x ULN | % Pts with event: 2.6% / 20843 persons | NR | NR |
| Melloni, 200887 | All-cause mortality | Followup NR | Assay: cTnT | 1-3 x ULN | % Pts with event: 2.2% / 5214 persons | NR | NR |
| Melloni, 200887 | All-cause mortality | Followup NR | Assay: cTnI | <1 x ULN | % Pts with event: 10.1% / 5529 persons | NR | NR |
| Melloni, 200887 | All-cause mortality | Followup NR | Assay: cTnI | >3 x ULN | % Pts with event: 14.6% / 20843 persons | NR | NR |
| Melloni, 200887 | All-cause mortality | Followup NR | Assay: cTnI | 1-3 x ULN | % Pts with event: 9.6% / 5214 persons | NR | NR |
| Melloni, 200887 | All-cause mortality | Followup NR | Assay: cTnT | <1 x ULN | % Pts with event: 7% / 5529 persons | NR | NR |
| Melloni, 200887 | All-cause mortality | Followup NR | Assay: cTnT | >3 x ULN | % Pts with event: 14% / 20843 persons | NR | NR |
| Melloni, 200887 | All-cause mortality | Followup NR | Assay: cTnT | 1-3 x ULN | % Pts with event: 5.7% / 5214 persons | NR | NR |
| Mockel, 199988 | All-cause mortality | Years: 1 | Assay: cTnI  Mfg: Dade Behring; opusplus | < 0.5 mcg/L | Pts with event: 2 / 16 persons | NR | NR |
| Mockel, 199988 | All-cause mortality | Years: 1 | Assay: cTnI  Mfg: Dade Behring; opusplus | > 0.5 mcg/L | Pts with event: 1 / 4 persons | NR | NR |
| Mockel, 199988 | All-cause mortality | Years: 1 | Assay: cTnI  Mfg: Dade Behring; stratus | < 0.4 mcg/L | Pts with event: 4 / 28 persons | NR | NR |
| Mockel, 199988 | All-cause mortality | Years: 1 | Assay: cTnI  Mfg: Dade Behring; stratus | > 0.4 mcg/L | Pts with event: 1 / 2 persons | NR | NR |
| Mockel, 199988 | All-cause mortality | Years: 1 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.1 mcg/L | Pts with event: 1 / 20 persons | NR | NR |
| Mockel, 199988 | All-cause mortality | Years: 1 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | Pts with event: 4 / 10 persons | NR | NR |
| Mockel, 199988 | MACE < 1 year | Years: 1 | Assay: cTnI  Mfg: Dade Behring; opusplus | > 0.5 mcg/L | NR | N: 7  OR: 4.57  95% CI: 0.4 to 5.2  p value: 0.22 | NR |
| Mockel, 199988 | MACE < 1 year | Years: 1 | Assay: cTnI  Mfg: Dade Behring; stratus | > 0.4 mcg/L | NR | N: 7  OR: 3.22  95% CI: 0.6 to 17  p value: 0.168 | NR |
| Mockel, 199988 | MACE < 1 year | Years: 1 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | NR | N: 7  OR: 1.63  95% CI: 0.18 to 5.9  p value: 0.969 | NR |
| Morton, 199889 | All-cause mortality | NR | NR | NR | Results: unadjusted | NR | Spec: 100% (for >1.5) |
| Morton, 199889 | All-cause mortality | NR | Assay: cTnI  Mfg: Sanofi; access | < 0.15 mcg/L | / 108 persons  Results: unadjusted | NR | Spec: 100% (for >1.5) |
| Morton, 199889 | All-cause mortality | NR | Assay: cTnI  Mfg: Sanofi; access | > 0.15 mcg/L< 1.5 mcg/L | / 4 persons  Results: unadjusted | NR | Spec: 100% (for >1.5) |
| Morton, 199889 | All-cause mortality | NR | Assay: cTnI  Mfg: Sanofi; access | > 1,5 mcg/L | Pts with event: 0  % Pts with event: 0% / 0 persons  Results: unadjusted | NR | Spec: 100% (for >1.5) |
| Musso, 199990 | All-cause mortality | NR | Assay: cTnI  Mfg: Dade Behring; stratus | < 0.4 mcg/L | Pts with event: 2 / 47 persons  Results: unadjusted | NR | NR |
| Musso, 199990 | All-cause mortality | NR | Assay: cTnI  Mfg: Dade Behring; stratus | > 0.4 mcg/L | Pts with event: 0 / 2 persons  Results: unadjusted | NR | NR |
| Musso, 199990 | All-cause mortality | NR | Assay: cTnI  Mfg: Sanofi; access | < 0.04 mcg/L | Pts with event: 2 / 49 persons  Results: unadjusted | NR | NR |
| Musso, 199990 | All-cause mortality | NR | Assay: cTnI  Mfg: Sanofi; access | > 0.4 mcg/L | Pts with event: 0 / 0 persons  Results: unadjusted | NR | NR |
| Musso, 199990 | All-cause mortality | NR | Assay: cTnT  Mfg: other  Mfg: Boerhinger; other; Enzymum | < 0.1 mcg/L | Pts with event: 2 / 26 persons  Results: unadjusted | NR | NR |
| Musso, 199990 | All-cause mortality | NR | Assay: cTnT  Mfg: other  Mfg: Boerhinger; other; Enzymum | > 0.1 mcg/L | Pts with event: 0 / 23 persons  Results: unadjusted | NR | NR |
| Musso, 199990 | MACE ≥ 1 year | NR | Assay: cTnI  Mfg: Dade Behring; stratus | < 0.4 mcg/L | Pts with event: 0 / 47 persons  Results: unadjusted | NR | NR |
| Musso, 199990 | MACE ≥ 1 year | NR | Assay: cTnI  Mfg: Dade Behring; stratus | > 0.4 mcg/L | Pts with event: 0 / 2 persons  Results: unadjusted | NR | NR |
| Musso, 199990 | MACE ≥ 1 year | NR | Assay: cTnI  Mfg: Sanofi; access | < 0.4 mcg/L | Pts with event: 0 / 49 persons  Results: unadjusted | NR | NR |
| Musso, 199990 | MACE ≥ 1 year | NR | Assay: cTnI  Mfg: Sanofi; access | > 0.4 mcg/L | Pts with event: 0 / 0 persons  Results: unadjusted | NR | NR |
| Musso, 199990 | MACE ≥ 1 year | NR | Assay: cTnT  Mfg: other  Mfg: Boerhinger; other; Enzymum | < 0.1 mcg/L | Pts with event: 0 / 26 persons  Results: unadjusted | NR | NR |
| Musso, 199990 | MACE ≥ 1 year | NR | Assay: cTnT  Mfg: other  Mfg: Boerhinger; other; Enzymum | > 0.1 mcg/L | Pts with event: 0 / 23 persons  Results: unadjusted | NR | NR |
| Ooi, 199992 | All-cause mortality | Years: 1 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.1 mcg/L | % Pts with event: 10% / 111 persons  Results: unadjusted | RR: 1 | NR |
| Ooi, 199992 | All-cause mortality | Years: 1 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | % Pts with event: 33% / 61 persons  Results: unadjusted | RR: 3.3  95% CI: 1.7 to 6.4  p value: <0.001;  ref group: Grp1 | NR |
| Ooi, 199992 | Cardio mortality | Years: 1 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.1 mcg/L | % Pts with event: 5% / 111 persons  Results: unadjusted | RR: 1 | NR |
| Ooi, 199992 | Cardio mortality | Years: 1 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | % Pts with event: 10% / 61 persons  Results: unadjusted | RR: 1.8  95% CI: 0.6 to 5.4  p value: ns;  ref group: Grp1 | NR |
| Ooi, 200193 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | < 0.01 mcg/L | Pts with event: 1  % Pts with event: 6% / 17 persons  Results: unadjusted | N: 17  RR: 1 | NR |
| Ooi, 200193 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.01 mcg/L< 0.099 mcg/L | Pts with event: 52  % Pts with event: 43% / 121 persons  Results: unadjusted | N: 121  RR: 7.3  95% CI: 1.1 to 49  p value: <0.005;  ref group: Grp1 | NR |
| Ooi, 200193 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | Pts with event: 34  % Pts with event: 59% / 58 persons  Results: unadjusted | N: 58  RR: 10  95% CI: 1.5 to 68  p value: <0.001;  ref group: Grp1 | NR |
| Ooi, 200193 | Cardio mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | < 0.01 mcg/L | Pts with event: 0 / 17 persons  Results: unadjusted | NR | NR |
| Ooi, 200193 | Cardio mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.01 mcg/L< 0.099 mcg/L | Pts with event: 17  % Pts with event: 14% / 121 persons  Results: unadjusted | NR | NR |
| Ooi, 200193 | Cardio mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | Pts with event: 14  % Pts with event: 24% / 58 persons  Results: unadjusted | NR | NR |
| Orea-Tejeda, 201094 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | NR | Results: adjusted | NR | NR |
| Orea-Tejeda, 201094 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | >=0.02 ng/mL | % Pts with event: 83.5% / 21 persons  Results: adjusted | NR | NR |
| Peetz, 200395 | MACE < 1 year | NR | NR | NR | Results: unadjusted | NR | AUC: 0.574  Sens: 16%  Spec: 93.70% |
| Peetz, 20095 | MACE < 1 year | NR | Assay: cTnI  Mfg: Dade Behring; stratus | < 0.4 mcg/L | Results: unadjusted | N: 101 (97.1%) | AUC: 0.574  Sens: 16%  Spec: 93.70% |
| Peetz, 200395 | MACE < 1 year | NR | Assay: cTnI  Mfg: Dade Behring; stratus | > 0.4 mcg/L | Results: unadjusted | N: 3 (2.9%) | AUC: 0.574  Sens: 16%  Spec: 93.70% |
| Peetz, 200395 | MACE < 1 year | NR | NR | NR | Results: unadjusted | NR | AUC: 0.708  Sens: 53.50%  Spec: 72.50% |
| Peetz, 200395 | MACE < 1 year | NR | Assay: cTnI  Mfg: Bayer; acs180 | < 0.15 mcg/L | Results: unadjusted | N: 70 (69.6%)  OR: REF | AUC: 0.708  Sens: 53.50%  Spec: 72.50% |
| Peetz, 200395 | MACE < 1 year | NR | Assay: cTnI  Mfg: Bayer; acs180 | > 0.15 mcg/L | Results: unadjusted | N: 34 (32.4%)  OR: 4  p value: 0.22;  ref group: Grp1 | AUC: 0.708  Sens: 53.50%  Spec: 72.50% |
| Peetz, 200395 | MACE < 1 year | NR | NR | NR | Results: unadjusted | NR | AUC: 0.726  Sens: 58.4  Spec: 77.9 |
| Peetz, 200395 | MACE < 1 year | NR | Assay: cTnT  Mfg: Roche; Elecsys | < 0.1 mcg/L | Results: unadjusted | N: 36 (34.6%)  OR: REF | AUC: 0.726  Sens: 58.4  Spec: 77.9 |
| Peetz, 200395 | MACE < 1 year | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | Results: unadjusted | N: 68 (65.7%)  OR: 16  p value: <0.01; ref group: Grp1 | AUC: 0.726  Sens: 58.4  Spec: 77.9 |
| Petrovic, 200996 | All-cause mortality | NR | Assay: cTnI  Mfg: other  Mfg: Abbott; ADV AxSYM cTnI Immunoassay | <0.15 ng/mL | % Pts with event: 2.41%  Results: unadjusted | NR | NR |
| Petrovic, 200996 | All-cause mortality | NR | Assay: cTnI  Mfg: other  Mfg: Abbott; ADV AxSYM cTnI Immunoassay | >0.15 ng/mL | % Pts with event: 15.62%  Results: unadjusted | NR | NR |
| Petrovic, 200996 | All-cause mortality | NR | NR | NR | Results: unadjusted | NR | AUC: 0.637  95% CI: 0.542 to 0.725  Sens: 0.5172  95% CI: 32.5 to 70.5  Spec: 0.814  95% CI: 71.6 to 89 |
| Petrovic, 200996 | All-cause mortality | NR | NR | NR | Results: unadjusted | NR | AUC: 0.744  95% CI: 0.654 to 0.821  Sens: 0.7586  95% CI: 56.5 to 89.7  Spec: 0.7209  95% CI: 61.4 to 81.2 |
| Petrovic, 200996 | All-cause mortality | NR | NR | <0.15 ng/mL | % Pts with event: 0%  Results: unadjusted | NR | NR |
| Petrovic, 200996 | All-cause mortality | NR | NR | >0.15 ng/mL | % Pts with event: 31.11%  Results: unadjusted | NR | NR |
| Petrovic, 200996 | All-cause mortality | NR | Assay: cTnI  Mfg: other  Mfg: Abbott; ADV AxSYM cTnI Immunoassay | <0.15 ng/mL | % Pts with event: 14.46%  Results: unadjusted | NR | NR |
| Petrovic, 200996 | All-cause mortality | NR | Assay: cTnI  Mfg: other  Mfg: Abbott; ADV AxSYM cTnI Immunoassay | <0.15 ng/mL | % Pts with event: 16.87%  Results: unadjusted | NR | AUC: 0.637  95% CI: 0.542 to 0.725  Sens: 0.5172  95% CI: 32.5 to 70.5  Spec: 0.814  95% CI: 71.6 to 89 |
| Petrovic, 200996 | All-cause mortality | NR | Assay: cTnI  Mfg: other  Mfg: Abbott; ADV AxSYM cTnI Immunoassay | <0.15 ng/mL | % Pts with event: 7.23%  Results: unadjusted | NR | NR |
| Petrovic, 200996 | All-cause mortality | NR | Assay: cTnI  Mfg: other  Mfg: Abbott; ADV AxSYM cTnI Immunoassay | >0.15 ng/mL | % Pts with event: 25%  Results: unadjusted | NR | NR |
| Petrovic, 200996 | All-cause mortality | NR | Assay: cTnI  Mfg: other  Mfg: Abbott; ADV AxSYM cTnI Immunoassay | >0.15 ng/mL | % Pts with event: 34.37%  Results: unadjusted | NR | NR |
| Petrovic, 200996 | All-cause mortality | NR | Assay: cTnI  Mfg: other  Mfg: Abbott; ADV AxSYM cTnI Immunoassay | >0.15 ng/mL | % Pts with event: 46.87%  Results: unadjusted | NR | AUC: 0.637  95% CI: 0.542 to 0.725  Sens: 0.5172  95% CI: 32.5 to 70.5  Spec: 0.814  95% CI: 71.6 to 89 |
| Petrovic, 200996 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | < 0.1 mcg/L | % Pts with event: 0%  Results: unadjusted | NR | NR |
| Petrovic, 200996 | All-cause mortality |  | Assay: cTnT  Mfg: Roche; Elecsys | < 0.1 mcg/L | % Pts with event: 2.86%  Results: unadjusted | NR | NR |
| Petrovic, 200996 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | < 0.1 mcg/L | % Pts with event: 2.86%  Results: unadjusted | NR | AUC: 0.744  95% CI: 0.654 to 0.821  Sens: 0.7586  95% CI: 56.5 to 89.7  Spec: 0.7209  95% CI: 61.4 to 81.2 |
| Petrovic, 200996 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | % Pts with event: 15.56%  Results: unadjusted | NR | NR |
| Petrovic, 200996 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | % Pts with event: 46.67%  Results: unadjusted | NR | NR |
| Petrovic, 200996 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | % Pts with event: 60%  Results: unadjusted | NR | AUC: 0.744  95% CI: 0.654 to 0.821  Sens: 0.7586  95% CI: 56.5 to 89.7  Spec: 0.7209  95% CI: 61.4 to 81.2 |
| Porter, 199897 | All-cause mortality | NR | NR | NR | NR | NR | Sens: 0.25  Spec: 0.909 |
| Porter, 199897 | All-cause mortality | NR | NR | NR | NR | NR | Sens: 0.875  Spec: 0.864 |
| Porter, 199897 | All-cause mortality | NR | NR | NR | Results: unadjusted | NR | Sens: 0.125  Spec: 0.955 |
| Porter, 199897 | All-cause mortality | NR | Assay: cTnI  Mfg: Dade Behring; NR | < 0.4 mcg/L | Pts with event: 4 / 28 persons  Results: unadjusted | NR | Sens: 0.125  Spec: 0.955 |
| Porter, 199897 | All-cause mortality | NR | Assay: cTnI  Mfg: Dade Behring; NR | < 0.5 mcg/L | Pts with event: 2 / 16 persons | NR | Sens: 0.25  Spec: 0.909 |
| Porter, 199897 | All-cause mortality | NR | Assay: cTnI  Mfg: Dade Behring; NR | > 0.4 mcg/L | Pts with event: 1 / 2 persons  Results: unadjusted | NR | Sens: 0.125  Spec: 0.955 |
| Porter, 199897 | All-cause mortality | NR | Assay: cTnI  Mfg: Dade Behring; NR | > 0.5 mcg/L | Pts with event: 1 / 4 persons | NR | Sens: 0.25  Spec: 0.909 |
| Porter, 199897 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; other; Enzymum | < 0.1 mcg/L | Pts with event: 1 / 20 persons | NR | Sens: 0.875  Spec: 0.864 |
| Porter, 199897 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; other; Enzymum | > 0.1 mcg/L | Pts with event: 4 / 10 persons | NR | Sens: 0.875  Spec: 0.864 |
| Porter, 200098 | All-cause mortality | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.1 mcg/L | Pts with event: 2 / 17 persons  Results: unadjusted | NR | NR |
| Porter, 200098 | All-cause mortality | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | Pts with event: 5 / 10 persons  Results: unadjusted | NR | NR |
| Porter, 200098 | MACE ≥ 1 year | Years: 2 | NR | NR | Results: unadjusted | NR | Sens: 18.2  Spec: 87.5 |
| Porter, 200098 | MACE ≥ 1 year | Years: 2 | NR | NR | Results: unadjusted | NR | Sens: 9.1  Spec: 87.5 |
| Porter, 200098 | MACE ≥ 1 year | Years: 2 | Assay: cTnI  Mfg: Dade Behring; stratus | < 0.4 mcg/L | Pts with event: 10 / 24 persons  Results: unadjusted |  | Sens: 9.1  Spec: 87.5 |
| Porter, 200098 | MACE ≥ 1 year | Years: 2 | Assay: cTnI  Mfg: Dade Behring; stratus | > 0.4 mcg/L | Pts with event: 1 / 3 persons  Results: unadjusted | NR | Sens: 9.1  Spec: 87.5 |
| Porter, 200098 | MACE ≥ 1 year | Years: 2 | Assay: cTnI  Mfg: other  Mfg: Abbott; other; AxSym | < 0.5 mcg/L | Pts with event: 9 / 23 persons  Results: unadjusted | NR | Sens: 18.2  Spec: 87.5 |
| Porter, 200098 | MACE ≥ 1 year | Years: 2 | Assay: cTnI  Mfg: other  Mfg: Abbott; other; AxSym | > 0.5 mcg/L | Pts with event: 2 / 4 persons  Results: unadjusted | NR | Sens: 18.2  Spec: 87.5 |
| Porter, 200098 | MACE ≥ 1 year | Years: 2 | NR | NR | Results: unadjusted | NR | Sens: 81.8  Spec: 88.2 |
| Porter, 200098 | MACE ≥ 1 year | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.1 mcg/L | Pts with event: 2 / 17 persons  Results: unadjusted | NR | Sens: 81.8  Spec: 88.2 |
| Porter, 200098 | MACE ≥ 1 year | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | Pts with event: 9 / 10 persons  Results: unadjusted | NR | Sens: 81.8  Spec: 88.2 |
| Quiroga, 201399 | Other composite (CV events + non-CV mortality) |  | Assay: cTnT  Mfg: Roche; other; ECLIA | > 0.01 ng/L | N: 218  % pts with event: 50%  pts with event: 23  Results: unadjusted | N: 218  OR: 2.07  95% CI: 1.03 to 4.16  p value: 0.042;  ref group: whole group | NR |
| Roberts, 2004100 | MACE < 1 year-Revascularization-Other composite |  | Assay: cTnI  Mfg: other  Mfg: Abott; other; Abott AXSYM | < 0.3 mcg/L | Pts with event: 5 / 79 persons  Results: unadjusted | N: 79  RR: 1 | NR |
| Roberts, 2004100 | MACE < 1 year-Revascularization-Other composite |  | Assay: cTnI  Mfg: other  Mfg: Abott; other; Abott AXSYM | > 0.3 mcg/L | Pts with event: 5 / 9 persons  Results: unadjusted | N: 9  RR: 8.8  95% CI: 1.8 to 31.8;  ref group: Grp1 | NR |
| Roberts, 2009101 | All-cause mortality | Years: 1.8 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.04 mcg/L | Pts with event: 0 / 28 persons | NR | NR |
| Roberts, 2009101 | All-cause mortality | Years: 1.8 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.04 mcg/L | Pts with event: 2 / 20 persons | NR | NR |
| Roberts, 2009101 | All-cause mortality | Years: 1.8 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.04 mcg/L | Pts with event: 7 / 33 persons | NR | NR |
| Roberts, 2009101 | Cardio mortality | Years: 1.8 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.04 mcg/L | Pts with event: 0 / 26 persons | NR | NR |
| Roberts, 2009101 | Cardio mortality | Years: 1.8 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.04 mcg/L | Pts with event: 1 / 17 persons | NR | NR |
| Roberts, 2009101 | Cardio mortality | Years: 1.8 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.04 mcg/L | Pts with event: 6 / 29 persons | NR | NR |
| Roppolo, 1999102 | MACE < 1 year | NR | Assay: cTnI  Mfg: Dade Behring; opus | > 0.5 mcg/L | Pts with event: 3 / 3 persons  Results: unadjusted | NR | NR |
| Roppolo, 1999102 | MACE < 1 year | NR | Assay: cTnT  Mfg: Dade Behring; opus | > 0.1 mcg/L | Pts with event: 6 / 24 persons  Results: unadjusted | NR | NR |
| Roppolo, 1999102 | MACE < 1 year | NR | Assay: cTnT  Mfg: Dade Behring; opus | > 0.2 mcg/L | Pts with event: 5 / 9 persons  Results: unadjusted | NR | NR |
| Sahinarslan, 2008103 | All-cause mortality | Years: 5 | Assay: cTnT  Mfg: NR; NR | < 0.1 mcg/L | % Pts with event: 16.4% / 61 persons  Results: unadjusted | NR | NR |
| Sahinarslan, 2008103 | All-cause mortality | Years: 5 | Assay: cTnT  Mfg: NR; NR | > 0.1 mcg/L | % Pts with event: 52.9% / 17 persons  Results: unadjusted | NR | NR |
| Sahinarslan, 2008103 | MACE ≥ 1 year | Years: 5 | Assay: cTnT  Mfg: NR; NR | < 0.1 mcg/L | % Pts with event: 24.6% / 61 persons  Results: adjusted | N: 61  OR: 1 | NR |
| Sahinarslan, 2008103 | MACE ≥ 1 year | Years: 5 | Assay: cTnT  Mfg: NR; NR | > 0.1 mcg/L | % Pts with event: 64.7% / 17 persons  Results: adjusted | N: 17  OR: 3.215  95% CI: 0.405 to 25.53  p value: 0.269;  ref group: Grp1 | NR |
| Satyan, 2007104 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.01 mcg/L< 0.022 mcg/L | Results: adjusted | N: 38  RH: 1 | NR |
| Satyan, 2007104 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.022 mcg/L< 0.056 mcg/L | Results: adjusted | N: 38  RH: 1.57  95% CI: 0.46 to 5.35  p value: 0.5;  ref group: Grp1 | NR |
| Satyan, 2007104 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.056 mcg/L< 0.106 mcg/L | Results: adjusted | N: 37  RH: 2.32  95% CI: 0.69 to 7.86  p value: 0.2;  ref group: Grp1 | NR |
| Satyan, 2007104 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.106 mcg/L< 0.569 mcg/L | Results: adjusted | N: 37  RH: 3.39  95% CI: 1.04 to 11.07  p value: 0.04;  ref group: Grp1 | NR |
| Satyan, 2007104 | Cardio mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.01 mcg/L< 0.022 mcg/L | Results: adjusted | N: 38  RH: 1 | NR |
| Satyan, 2007104 | Cardio mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.022 mcg/L< 0.056 mcg/L | Results: adjusted | N: 38  RH: 0.81  95% CI: 0.16 to 4.06  p value: 0.8;  ref group: Grp1 | NR |
| Satyan, 2007104 | Cardio mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.056 mcg/L< 0.106 mcg/L | Results: adjusted | N: 37  RH: 2.12  95% CI: 0.47 to 9.54  p value: 0.34;  ref group: Grp1 | NR |
| Satyan, 2007104 | Cardio mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.106 mcg/L< 0.569 mcg/L | Results: adjusted | N: 37  RH: 2.14  95% CI: 0.48 to 9.6  p value: 0.32;  ref group: Grp1 | NR |
| Scott, 2003106 | All-cause mortality | Years: 1 | Assay: cTnT  Mfg: other  Mfg: Boehringer Mannheim; other; Cardiac reader | < 0.1 mcg/L | Pts with event:  % Pts with event: 17% / 42 persons  Results: unadjusted | N: 42  Coefficient: REF  SE: 2.185 | NR |
| Scott, 2003106 | All-cause mortality | Years: 1 | Assay: cTnT  Mfg: other  Mfg: Boehringer Mannheim; other; Cardiac reader | > 0.1 mcg/L | % Pts with event: 41% / 29 persons  Results: unadjusted | N: 29 (40.8%)  Coefficient: 4.988  SE: 2.185  95% CI: 10645.93 to 2.023  p value: 0.0025;  ref group: Grp1 | NR |
| Sharma, 2005107 | All-cause mortality | Years: 2.12 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.1 mcg/L | Pts with event: 0 / 87 persons  Results: unadjusted | N: 87 | AUC: 0.76  p value: 0.02  95% CI: 0.617 to 0.935 |
| Sharma, 2005107 | All-cause mortality | Years: 2.12 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | Pts with event: 5 / 31 persons  Results: unadjusted | N: 31  AUC: 0.76  95% CI: 0.617 to 0.935  p value: 0.02;  ref group: Grp1 | NR |
| Sharma, 2006108 | All-cause mortality | Years: 2.25 | NR | NR | Results: unadjusted | NR | AUC: 0.82  p value: 0.02  95% CI: 0.99 to 0.64  Sens: 75  Spec: 72 |
| Sharma, 2006108 | All-cause mortality | Years: 2.25 | NR | NR | Results: unadjusted | NR | AUC: 0.82  p value: 0.02  95% CI: 0.99 to 0.64  Sens: 75  Spec: 72 |
| Sharma, 2006108 | All-cause mortality | Years: 2.25 | NR | NR | Results: unadjusted | NR | AUC: 0.82  p value: 0.02  95% CI: 0.99 to 0.64  Sens: 75  Spec: 72 |
| Sharma, 2006108 | All-cause mortality | Years: 2.25 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.06 mcg/L | Results: unadjusted | N: 51  OR: 7.14  95% CI: 5.71 to 10.22  p value: 0.004;  ref group: Grp2 | AUC: 0.82  p value: 0.02  95% CI: 0.99 to 0.64  Sens: 75  Spec: 72 |
| Sharma, 2006108 | All-cause mortality | Years: 2.25 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.06 mcg/L | Results: unadjusted | N: 62 | AUC: 0.82  p value: 0.02  95% CI: 0.99 to 0.64  Sens: 75  Spec: 72 |
| Sharma, 2006109 | All-cause mortality | Years: 2.5 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.04 mcg/L | Pts with event: 3 / 74 persons  Results: unadjusted | NR | NR |
| Sharma, 2006109 | All-cause mortality | Years: 2.5 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.1 mcg/L | Pts with event: 6 / 88 persons  Results: unadjusted | NR | NR |
| Sharma, 2006109 | All-cause mortality | Years: 2.5 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.04 mcg/L | Pts with event: 17 / 52 persons  Results: unadjusted | NR | NR |
| Sharma, 2006109 | All-cause mortality | Years: 2.5 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | Pts with event: 14 / 38 persons  Results: unadjusted | NR | NR |
| Shroff, 2012110 | All-cause mortality | Years: 1 | Assay: cTnI  Mfg: other  Mfg: Ortho Clinical Diagnostics; Vitros | <0.04 ng/mL | Pts with event: 5 / 281 persons  Results: unadjusted | NR | NR |
| Shroff, 2012110 | All-cause mortality | Years: 1 | Assay: cTnI  Mfg: other  Mfg: Ortho Clinical Diagnostics; Vitros | >0.04 ng>mL | Pts with event: 3 / 95 persons  Results: unadjusted | NR | NR |
| Shroff, 2012110 | MACE < 1 year | Years: 1 | Assay: cTnI  Mfg: other  Mfg: Ortho Clinical Diagnostics; Vitros | <0.04 ng/mL | No. of events: 4 / 281 persons  Results: unadjusted | NR | NR |
| Shroff, 2012110 | MACE < 1 year | Years: 1 | Assay: cTnI  Mfg: other  Mfg: Ortho Clinical Diagnostics; Vitros | >0.04 ng>mL | No. of events: 5 / 95 persons  Results: unadjusted | NR | NR |
| Sommerer, 2007111 | MACE ≥ 1 year | NR | Assay: cTnI  Mfg: Roche; Elecsys | > 0.026 mcg/L | Results: adjusted | N: 53 (39.6%)  OR: 2.12  SE: NR  95% CI: 1.24 to 3.62  p value: 0.006;  ref group: Grp1 | NR |
| Sommerer, 2007111 | MACE ≥ 1 year | NR | Assay: cTnT  Mfg: Roche; Elecsys | < 0.026 mcg/L | Results: adjusted | N: 81  OR: REF  SE: NR | NR |
| Stolear, 1999112 | All-cause mortality | NR | Assay: cTnT  Mfg: other  Mfg: Boehringer Mannheim; Elecsys | < 0.1 mcg/L | Pts with event: 6  % Pts with event: 13% / 47 persons  Results: adjusted | N: 47 | NR |
| Stolear, 1999112 | All-cause mortality | NR | Assay: cTnT  Mfg: other  Mfg: Boehringer Mannheim; Elecsys | > 0.1 mcg/L | Pts with event: 18  % Pts with event: 38% / 47 persons  Results: adjusted | N: 47  beta coefficient in Cox model: 2.74  SE: 0.69  p value: 0.0001;  ref group: Grp1 | NR |
| Stolear, 1999112 | All-cause mortality | NR | Assay: cTnT  Mfg: other  Mfg: Boehringer; other; TROP T RA -rapid beside assay | < 0.2 mcg/L | Pts with event: 2 / 44 persons  Results: adjusted | NR | NR |
| Stolear, 1999112 | All-cause mortality | NR | Assay: cTnT  Mfg: other  Mfg: Boehringer; other; TROP TRA - rapid assay | > 0.2 mcg/L | Pts with event: 22 / 50 persons  Results: adjusted | NR | NR |
| Stolear, 1999112 | Subs. MI |  | Assay: cTnT  Mfg: other  Mfg: Boehringer; Elecsys | < 0.1 mcg/L | Pts with event: 0 / 47 persons  Results: unadjusted | NR | NR |
| Stolear, 1999112 | Subs. MI |  | Assay: cTnT  Mfg: other  Mfg: Boehringer; Elecsys | > 0.1 mcg/L | Pts with event: 2 / 47 persons  Results: unadjusted | NR | NR |
| Svensson, 2009114 | All-cause mortality | Years: 2 | Assay: cTnT  Mfg: NR; NR | NR | Results: adjusted | N: 206  HR: 1.76  95% CI: 0.32 to 9.69  p value: 0.52;  ref group: other;  ref group: Total sample | NR |
| Trape, 2008115 | All-cause mortality | Years: 1 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.1 mcg/L | Pts with event: 4 / 39 persons  Results: unadjusted | NR | NR |
| Trape, 2008115 | All-cause mortality | Years: 1 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | Pts with event: 5 / 13 persons  Results: unadjusted | NR | NR |
| Trape, 2008115 | All-cause mortality | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.1 mcg/L | Pts with event: 11 / 39 persons  Results: unadjusted | NR | NR |
| Trape, 2008115 | All-cause mortality | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | Pts with event: 8 / 13 persons  Results: unadjusted | NR | NR |
| Trape, 2008115 | All-cause mortality | Years: 3 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.1 mcg/L | Pts with event: 18 / 39 persons  Results: unadjusted | NR | NR |
| Trape, 2008115 | All-cause mortality | Years: 3 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | Pts with event: 10 / 13 persons  Results: unadjusted | NR | NR |
| Troyanov, 2005116 | Other composite (ACS occurrence) | Years: 3 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.4 mcg/L | NR | N: 29  Unadjusted HR: 2.98  95% CI: 8.57 to 1.04  p value: 0.04 | NR |
| Troyanov, 2005116 | Other composite (ACS occurrence) | Years: 3 | Assay: cTnI  Mfg: other  Mfg: Abbot Laboratories; other; MEIA, AxSYM | > 0.3 mcg/L | NR | N: 29  unadjusted HR: 3.37  95% CI: 7.25 to 1.56  p value: 0.001 | NR |
| Van Lente, 1999117 | MACE < 1 year-Revascularization |  | NR |  | Results: unadjusted | NR | AUC: 0.59  p value: <0.01  Sens: 0.45  Spec: 0.72 |
| Van Lente, 1999117 | MACE < 1 year-Revascularization |  | NR |  | Results: unadjusted | NR | AUC: 0.53  p value: <0.02  Sens: 0.33  Spec: 0.78 |
| Van Lente, 1999117 | MACE < 1 year-Revascularization |  | Assay: cTnI  Mfg: Dade Behring; stratus | Threshold 0.6 mcg/L | Results: unadjusted | NR | AUC: 0.53  p value: <0.02  Sens: 0.33  Spec: 0.78 |
| Van Lente, 1999117 | MACE < 1 year-Revascularization |  | Assay: cTnT  Mfg: other  Mfg: Boehringer; other; Enzymun | Threshold 0.10 mcg/L | Results: unadjusted | NR | AUC: 0.59  p value: <0.01  Sens: 0.45  Spec: 0.72 |
| Vichairuangthum, 2006118 | Cardio mortality |  | Assay: cTnI  Mfg: other  Mfg: Johnson & Johnson; other; Vitros ECi | < 0.08 mcg/L | Pts with event: 0 / 16 persons  Results: unadjusted | NR | NR |
| Vichairuangthum, 2006118 | Cardio mortality | NR | Assay: cTnI  Mfg: other  Mfg: Johnson & Johnson; other; Vitros ECi | < 0.4 mcg/L | Pts with event: 2 / 49 persons  Results: unadjusted | NR | NR |
| Vichairuangthum, 2006118 | Cardio mortality | NR | Assay: cTnI  Mfg: other  Mfg: Johnson & Johnson; other; Vitros ECi | > 0.08 mcg/L | Pts with event: 2 / 47 persons  Results: unadjusted | NR | NR |
| Vichairuangthum, 2006118 | Cardio mortality | NR | Assay: cTnI  Mfg: other  Mfg: Johnson & Johnson; other; Vitros ECi | > 0.4 mcg/L | Pts with event: 0 / 14 persons  Results: unadjusted | NR | NR |
| Vichairuangthum, 2006118 | MACE ≥ 1 year | NR | Assay: cTnI  Mfg: other  Mfg: Johnson & Johnson; other; Vitros ECi | < 0.08 mcg/L | Pts with event: 0 / 16 persons  Results: unadjusted | NR | NR |
| Vichairuangthum, 2006118 | MACE ≥ 1 year | NR | Assay: cTnI  Mfg: other  Mfg: Johnson & Johnson; other; Vitros ECi | < 0.4 mcg/L | Pts with event: 5 / 49 persons  Results: unadjusted | NR | NR |
| Vichairuangthum, 2006118 | MACE ≥ 1 year | NR | Assay: cTnI  Mfg: other  Mfg: Johnson & Johnson; other; Vitros ECi | > 0.08 mcg/L | Pts with event: 10 / 47 persons  Results: unadjusted | NR | NR |
| Vichairuangthum, 2006118 | MACE ≥ 1 year | NR | Assay: cTnI  Mfg: other  Mfg: Johnson & Johnson; other; Vitros ECi | > 0.4 mcg/L | Pts with event: 5 / 14 persons  Results: unadjusted | NR | NR |
| Vichairuangthum, 2006118 | Subs. MI | NR | Assay: cTnI  Mfg: other  Mfg: Johnson & Johnson; other; Vitros ECi | < 0.08 mcg/L | Pts with event: 0 / 16 persons  Results: unadjusted | NR | NR |
| Vichairuangthum, 2006118 | Subs. MI | NR | Assay: cTnI  Mfg: other  Mfg: Johnson & Johnson; other; Vitros ECi | < 0.4 mcg/L | Pts with event: 0 / 49 persons  Results: unadjusted | NR | NR |
| Vichairuangthum, 2006118 | Subs. MI | NR | Assay: cTnI  Mfg: other  Mfg: Johnson & Johnson; other; Vitros ECi | > 0.08 mcg/L | Pts with event: 1 / 47 persons  Results: unadjusted | NR | NR |
| Vichairuangthum, 2006118 | Subs. MI | NR | Assay: cTnI  Mfg: other  Mfg: Johnson & Johnson; other; Vitros ECi | > 0.4 mcg/L | Pts with event: 1 / 14 persons  Results: unadjusted | NR | NR |
| Wang, 2006119 | Other composite (cardio congestion) | Years: 3 | Assay: cTnT  Mfg: Roche; other; Roche Modular Analyzer | per 1 ug/L increase (cont.) | Pts with event: 85 / 222 persons  Results: adjusted | N: 85  RH: 2.98  95% CI: 1.19 to 7.42  p value: 0.019;  ref group: other;  ref group: total population | NR |
| Wang, 2007120 | All-cause mortality | NR | NR | NR | Results: adjusted | NR | Sens: 0.76  95% CI: 0.64 to 0.85  Spec: 0.71  95% CI: 0.63 to 0.78 |
| Wang, 2007120 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | < 0.01 mcg/L | Pts with event: 9 / 77 persons  Results: adjusted | NR | Sens: 0.76  95% CI: 0.64 to 0.85  Spec: 0.71  95% CI: 0.63 to 0.78 |
| Wang, 2007120 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.01 mcg/L< 0.099 mcg/L | Pts with event: 15 / 78 persons  Results: adjusted | NR | Sens: 0.76  95% CI: 0.64 to 0.85  Spec: 0.71  95% CI: 0.63 to 0.78 |
| Wang, 2007120 | All-cause mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | Pts with event: 46 / 83 persons  Results: adjusted | NR | Sens: 0.76  95% CI: 0.64 to 0.85  Spec: 0.71  95% CI: 0.63 to 0.78 |
| Wang, 2007120 | Cardio mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | < 0.01 mcg/L | Pts with event: 6 / 77 persons  Results: adjusted | NR | NR |
| Wang, 2007120 | Cardio mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.01 mcg/L< 0.099 mcg/L | Pts with event: 9 / 78 persons  Results: adjusted | NR | NR |
| Wang, 2007120 | Cardio mortality | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | Pts with event: 29 / 83 persons  Results: adjusted | NR | NR |
| Wang, 2007120 | MACE ≥ 1 year | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.01 mcg/L< 0.099 mcg/L | Pts with event: 37 / 78 persons  Results: adjusted | NR | Sens: 0.61  95% CI: 0.52 to 0.69  Spec: 0.78  95% CI: 0.69 to 0.85 |
| Wang, 2007120 | MACE ≥ 1 year | NR | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | Pts with event: 66 / 83 persons  Results: adjusted | NR | Sens: 0.61  95% CI: 0.52 to 0.69  Spec: 0.78  95% CI: 0.69 to 0.85 |
| Wang, 2007120 | MACE ≥ 1 year | NR | Assay: cTnT  Mfg: Roche; Elecsys | < 0.01 mcg/L | Pts with event: 26 / 77 persons  Results: adjusted | NR | Sens: 0.61  95% CI: 0.52 to 0.69  Spec: 0.78  95% CI: 0.69 to 0.85 |
| Wang, 2007120 | MACE ≥ 1 year | NR | NR | NR | Results: adjusted | NR | Sens: 0.61  95% CI: 0.52 to 0.69  Spec: 0.78  95% CI: 0.69 to 0.85 |
| Wang, 2010121 | Cardio mortality | Years: 5 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.01 mcg/L | Results: adjusted | N: 81  RH: 1 | NR |
| Wang, 2010121 | Cardio mortality | Years: 5 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | Results: adjusted | N: 79  RH: 2.58  95% CI: 0.78 to 8.57  p value: 0.13;  ref group: Grp1 | NR |
| Wang, 2010121 | Cardio mortality | Years: 5 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.01 mcg/L< 0.099 mcg/L | Results: adjusted | N: 70  RH: 1.91  95% CI: 0.58 to 6.32  p value: 0.29;  ref group: Grp1 | NR |
| Wang, 2010122 | Other composite | Years: 5 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.01 mcg/L | % Pts with event: 8.1% / 81 persons | NR | NR |
| Wang, 2010122 | Other composite | Years: 5 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.01 mcg/L< 0.099 mcg/L | % Pts with event: 18.7% / 70 persons | NR | NR |
| Wang, 2010122 | Other composite | Years: 5 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | % Pts with event: 28.5% / 79 persons | NR | NR |
| Wayand, 2000123 | All-cause mortality | Years: 2 | NR | NR | NR | NR | AUC: 0.477  Sens: 0.57  Spec: 0.67 |
| Wayand, 2000123 | All-cause mortality | Years: 2 | Assay: cTnI  Mfg: Dade Behring; stratus | < 0.4 mcg/L | Pts with event: 3 / 31 persons | NR | AUC: 0.477  Sens: 0.57  Spec: 0.67 |
| Wayand, 2000123 | All-cause mortality | Years: 2 | Assay: cTnI  Mfg: Dade Behring; stratus | > 0.4 mcg/L | Pts with event: 2 / 28 persons | NR | AUC: 0.477  Sens: 0.57  Spec: 0.67 |
| Wayand, 2000123 | All-cause mortality | Years: 2 | NR | NR | NR | NR | AUC: 0.703  p value: 0.213  Sens: 0.57  Spec: 0.88 |
| Wayand, 2000123 | All-cause mortality | Years: 2 | Assay: cTnT  Mfg: Roche; other; Enzymum Troponin T - ES700 | < 0.1 mcg/L | Pts with event: 1 / 31 persons | NR | AUC: 0.703  p value: 0.213  Sens: 0.57  Spec: 0.88 |
| Wayand, 2000123 | All-cause mortality | Years: 2 | Assay: cTnT  Mfg: Roche; other; Enzymum Troponin T - ES700 | > 0.1 mcg/L | Pts with event: 4 / 28 persons | NR | AUC: 0.703  p value: 0.213  Sens: 0.57  Spec: 0.88 |
| Wolley, 2013124 | Cardio mortality | NR | Assay: hcTnT  Mfg: Roche; other; Automated Chemiluminescent Immunoassay | < 14 ng/L | Results: unadjusted | OR: 1 | NR |
| Wolley, 2013124 | Cardio mortality | NR | Assay: hcTnT  Mfg: Roche; other; Automated Chemiluminescent Immunoassay | > 14 ng/L | Results: unadjusted | OR: 1.506  95% CI: 1.182 to 1.918  ref group: cont. | NR |
| Wood, 2003125 | All-cause mortality | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.1 mcg/L | % Pts with event: 14%  No. of events: 10 / 71 persons  Results: adjusted | N: 71  RH: | NR |
| Wood, 2003125 | All-cause mortality | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | % Pts with event: 52%  No. of events: 11 / 25 persons  Results: adjusted | N: 25  RH: 1.72  95% CI: 1.08 to 2.74  p value: 0.02;  ref group: Grp1 | NR |
| Wood, 2003125 | Cardio mortality | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | < 0.1 mcg/L | No. of events: 5 / 71 persons | NR | NR |
| Wood, 2003125 | Cardio mortality | Years: 2 | Assay: cTnT  Mfg: Roche; Elecsys | > 0.1 mcg/L | No. of events: 6 / 25 persons | NR | NR |
| Yakupoglu, 2002126 | Cardio mortality | NR | Assay: cTnI  Mfg: other  Mfg: Diagnostic Products; immulite | < 2.3 mcg/L | Pts with event: 10  % Pts with event: 33% / 30 persons  Results: unadjusted | NR | NR |
| Yakupoglu, 2002126 | Cardio mortality | NR | Assay: cTnI  Mfg: other  Mfg: Diagnostic Products; immulite | > 2.3 mcg/L | Pts with event: 6  % Pts with event: 75% / 8 persons  Results: unadjusted | NR | NR |
| Yakupoglu, 2002126 | Other composite (survival) | NR | Assay: cTnI  Mfg: other  Mfg: Diagnostic Products; immulite | < 2.3 mcg/L | % Pts with event: 66.1% / 30 persons  Results: unadjusted | NR | NR |
| Yakupoglu, 2002126 | Other composite (survival) | NR | Assay: cTnI  Mfg: other  Mfg: Diagnostic Products; immulite | > 2.3 mcg/L | % Pts with event: 25% / 8 persons  Results: unadjusted | NR | NR |

Abbreviations: ACE=adverse cardiovascular event; AUC=area under the curve; cardio=cardiovascular; CI=confidence interval; cont.=continuous; cTnI=cardiac troponin I; cTnT=cardian troponin T; Grp=group; HR=hazard ratio; hs=high sensitivity; lab=laboratory; LR=likelihood ratio; MACE=major adverse cardiac events; mcg/L=micrograms per liter; Mfg=manufacturer; MI=myocardial infarction; N=number; ng/mL=nanograms per liter; ng/L=nanograms per liter; NR=not reported; ns=not specified; pts=patients; ref=reference; OR=odds ratio; revasc=revascularization; RH=relative;RR=relative risk; hazard; sd=standard deviation; se=standard error; sens=sensitivity; spec=specificity; subs.=subsequent